

CURRICULUM VITAE – 20JAN2026

**CARLOS GUSTAVO WAMBIER, M.D., Ph.D.**

*Associate Professor of Dermatology, Clinician Educator  
The Warren Alpert Medical School at Brown University  
Dermatology Clinical Trials Center, Rhode Island Hospital, 593 Eddy Street  
Jane Brown Building, 1<sup>st</sup> floor, Room 115, Providence, RI 02903  
Phone: (401) 738-4323 Fax:(401) 738-3857  
[carlos\\_wambier@brown.edu](mailto:carlos_wambier@brown.edu)*

**MEDICAL EDUCATION**

- Professional Degree**      **Medical Doctor (M.D.)**  
University of Sao Paulo, Ribeirao Preto School of Medicine  
Feb 1999 to Dec 2004
- Academic Degree**      **Doctor of Philosophy (Ph.D.) in Dermatology**  
University of Sao Paulo, Ribeirao Preto School of Medicine  
Internal Medicine Postgraduation Program.  
Division of Dermatology, Department of Internal Medicine  
Feb 2009 to Feb 2012  
*Doctoral Thesis: "The role of nuclear factor kappa B (NF-kappa B) activation in the cutaneous expression of Leprosy"*

**MEDICAL POSTGRADUATE TRAINING**

- Medical Fellowship**      **Tropical Medicine (Tropical Infectious Diseases)**  
Tropical Medicine Foundation "Doutor Heitor Vieira Dourado"  
Feb 2005 to Jan 2006.
- Medical Residency**      **Dermatology**  
Hospital of Clinics of Ribeirao Preto Medical School  
University of Sao Paulo. Dermatology Residency Program.  
Feb 2006 to Feb 2009.
- Observational Fellow**      **Visiting Scholar**  
Department of Dermatology, Brigham and Women's Hospital.  
Harvard Medical School - May 2013
- Post-doctorate**      **Dermatology Clinical Research and Clinical Trials**  
Yale School of Medicine, Department of Dermatology  
July 2018 to Dec 2019

**SCIENTIFIC IMPACT**

- Citations**      **3543. h-index: 29. i10-index:66**  
<https://scholar.google.com/citations?user=sDjv2lwAAAAJ>

## **POSTGRADUATE HONORS AND AWARDS**

- 2005 Highest overall ranking score. 2005 Residency Entrance Examinations, Medical Residency Committee of Hospital of Clinics of Ribeirao Preto Medical School, University of Sao Paulo. Ribeirao Preto, SP, Brazil.
- 2005 Honorary Crew Member of "Carlos Chagas Ship for Hospital Care" Brazilian Navy.
- 2008 1<sup>st</sup> place award in: VIII annual Photography Contest of the Hospital of Clinics of Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil.
- 2009 2<sup>nd</sup> place award in: 1<sup>st</sup> International Dermatology Photography Contest, DermQuest.com, Derm101. "Disseminated Bullous Cutaneous Larva Migrans"
- 2011 Dr. Diltor Vladimir Araujo Opromolla Award - for scientific investigation in Sanitary Dermatology (Endemic Infectious Diseases), Brazilian Society of Dermatology (SBD).
- 2011 1<sup>st</sup> place award in: Scientific Investigation in the XVI Annual Meeting of Dermatologists of Sao Paulo State (RADESP-SBD), 2011.
- 2016 1<sup>st</sup> place award in: 21<sup>st</sup> International Meeting of Dentistry – Brazilian Association of Dentistry (ABO). "Pemphigus Vulgaris in a young adult – case report".
- 2019 Periocular Deep Chemical Peel before-after photography featured in the cover of the 40<sup>th</sup> anniversary issue of the Journal of the American Academy of Dermatology, issue of 2 CME Articles about Chemical Peels, Aug 2019.
- 2021 "Editor's picks for the year 2020", Journal of the European Academy of Dermatology and Venereology (2 articles mentioned), Jan 2021.
- 2021 Invited Lecture at the Brazilian National Academy of Medicine, "Androgen Vulnerability to COVID19: A new therapeutic frontier".
- 2021 TOP CITED ARTICLE 2019-2020 Drug Development Research – Wiley.
- 2021 Dermie Awards - Nominated for Best Overall Dermatology Article 2020 – Dermasphere Podcast. Awarded Runner-up Best Overall: Episode 29: COVID pts are bald. Wambier CG et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19. The "Gabrin sign". JAAD Aug 2020. <https://dermaspherepodcast.com/favorites>
- 2022 "Cureus Laurate" Title, in recognition of extraordinary contributions to the Cureus Journal of Medical Science, April 12, 2022.
- 2022 Ranked among the most cited articles of the Journal of American Academy of Dermatology, 2018-2022. <https://www.journals.elsevier.com/journal-of-the-american-academy-of-dermatology/most-cited-articles>
- 2022 Doximity Ranked: Most Mentioned 2021 (top 10% mentioned clinician in the press), Doximity Ranked: Most Cited 2021 (top 10% cited for the year)  
Doximity Ranked: Most Published 2021 (top 10% published for the year)
- 2022 1<sup>st</sup> place award in: in vitro/in vivo studies, and 2<sup>nd</sup> place overall Pharmacognosy Meeting 2022, Brazil: "Evaluation of pro-collagen activity of Croton oil an *in vivo* experiment".
- 2023 Doximity Ranked: Doximity Ranked: Most Cited 2022 (top 10% cited for the year)  
Doximity Ranked: Most Published 2022 (top 10% published for the year)
- 2024 Nominated for Full Membership in Sigma Xi, The Scientific Research Honor Society, in recognition of scholarly achievements and contributions in the Field of Dermatology.  
Doximity Ranked: Most Published 2024 (top 10% published for the year)
- 2025 IMCAS Americas Honor Speaker Prize – Gala Dinner, São Paulo, Brazil.

2026 Doximity Ranked: Doximity Ranked: Most Cited 2025 (top 10% cited for the year)  
Doximity Ranked: Most Published 2025 (top 10% published for the year)

**MILITARY SERVICE**

Brazilian Navy, Jan 2005 to Jan 2006. Licensed as 1<sup>st</sup> Lieutenant of the reserve in Jan 2006.

Medical Doctor (MD), in the 9<sup>th</sup> Naval District (Western Amazon)

Extensive experience in Tropical Medicine and Tropical Infectious Diseases.

Promoted health and education. Treated multiple endemic infectious diseases in isolated native tribes and riverside communities.

**PROFESSIONAL LICENSES AND MEDICAL SPECIALTY BOARD CERTIFICATION**

2020-	Full license, Rhode Island Board of Medical Licensure and Discipline.
2018-	Full license, Connecticut Board of Medicine.
2023-	Full license, Wisconsin Board of Medicine.
2024-	Full license, Florida Board of Medicine.
2025-2025	Temporary license, Illinois Board of Medicine.
2009-	Full license, Paraná Board of Medicine, Brazil.
2004-2018	Full license, Sao Paulo Board of Medicine, Brazil.
2005-2005	Full license, Amazonas Board of Medicine, Brazil.
2019	Temporary license, Medical Council of India (Visiting Physician).
2024	Temporary license, Principality of Monaco.
2009	Diplomate, Brazilian Board of Dermatology (AMB-SBD).

**CURRENT CERTIFICATIONS**

Advanced Cardiac Life Support Provider, American Heart Association.

Basic Life Support Provider, American Heart Association.

**ACADEMIC APPOINTMENTS**

02/2009-09/2011	Instructor. Division of Dermatology, University of Sao Paulo.
02/2009-02/2012	Associate Research Scientist. Div. of Dermatology, University of Sao Paulo.
08/2010-09/2011	Assistant Professor of Dermatology. University of Ribeirao Preto.
06/2013-12/2018	Associate Professor (Tenure-track). Medicine, State Univ. of Ponta Grossa.
01/2019-12/2019	Postdoctoral Associate, Dept. of Dermatology, Yale School of Medicine.
01/2020 – 05/2023	Assistant Professor of Dermatology, Clinician Educator, Department of Dermatology, The Warren Alpert Medical School of Brown University.
06/2023 – current	Associate Professor of Dermatology, Clinician Educator, Department of Dermatology, The Warren Alpert Medical School of Brown University.

**DEPARTMENT LEADERSHIP APPOINTMENTS**

Director of Cosmetic Research. Department of Dermatology, The Warren Alpert Medical School of Brown University. 01/2020 – 01/2021

Medical Director of Clinical Trials. Dermatology Clinical Trials Center (DCTC), Department of Dermatology Dermatopharmacology Unit, Rhode Island Hospital. 01/2021 – Present.

Director of the Center for Laser and Aesthetics, Brown Dermatology, Inc. 09/2022 – Present.

Director of the Brown University Health Center for Regenerative Dermatology. 09/2024 – Present.

**UNIVERSITY COMMITTEES**

Collaborator Member, Pharmaceutical Sciences Postgraduation Program, Sector of Biological Sciences and Health, State University of Ponta Grossa. 02/2016-Present.

Permanent Member, Health Sciences Postgraduation Program, Sector of Biological Sciences and Health, State University of Ponta Grossa. 02/2017-12/2018.

**HOSPITAL APPOINTMENTS**

02/2009 – 02/2012 Hospital of Clinics – Ribeirao Preto (HCFMRP-USP), Brazil, Active.

08/2010 – 12/2011 Hospital Electro Bonini (HEB-UNAERP), Brazil, Active.

01/2013-10/2019 University Regional Hospital Wallace Thadeu de Mello e Silva (HURCG), Brazil, Active.

01/2011 – 11/2019 General Hospital UNIMED (HGU), Brazil, Active.

06/2021 – 10/2021 Samel Hospital, Brazil, Research Collaborator.

05/2021– present Rhode Island Hospital, RI, Active Member.

05/2021 – present The Miriam Hospital, RI, Active Member.

**OTHER APPOINTMENTS**

Ad hoc Reviewer, Research grants committee, Dermatology, Araucaria Foundation, 2015.

Ad hoc Reviewer, Grant implementation research committee, Americas Region, WHO, 2016–2017.

Ad hoc Reviewer, COVID-19 Grants reviewer committee, Austrian Science Fund (FWF), 2020.

Ad hoc Evaluator, COVID-19 Final Project Reports, Austrian Science Fund (FWF), 2023.

Institutional Reviewer, Brown Physicians Inc, BPI Academic Assessment Grant Program 2022–2023.

Dermatology Research Unit, Rhode Island Hospital, Data Safety Monitoring Board, 2020 – 2021.

Member, Board of Examiners, Brazilian Board of Dermatology, SBD, 2016.

Oral examiner, Brazilian Board of Dermatology, SBD, 2016.

Medical Director, Wambier Clinic, Ponta Grossa, PR, Brazil. 01/2013-07/2018.

Consultant, Dermatology in Rede Massa, SBT (Regional and National TV network); Bimonthly interviews about dermatology diagnoses and recent dermatology news, 01/2013-06/2018.

Speaker, Galderma Laboratories, 2016–2018, Photodynamic therapy.

Speaker, Cynosure Inc., Worldwide, 2015-2021, Lasers.

Speaker, Pfizer Inc, USA, 2023-2024, Alopecia Areata.

Advisory Board Member, Allergan Inc, Brazil, 2017-2019, Chemical Lipolysis.

Advisory Board, Incyte, USA, 2023, Vitiligo.

Advisor, Young Pharmaceuticals, Inc, 2018–present, Skincare.

Advisor, ChemistryRx, 2021–present, Injectables for Alopecia.

Advisor, Applied Biology, Inc, 2020-2021, Hair research.  
Advisor, Vydence, 2023-2024, Lasers.  
Advisor, Daniel Alain, 2023–present, Hair.  
Scientific Council Member, International Peeling Society (IPS) 2017–present.  
Vice-President, International Peeling Society (IPS), 2024–2026.  
President-Elect, International Peeling Society (IPS), 2026-2028.  
Chair, Mentorship Committee, International Peeling Society USA (IPS-USA) 2021–2023.  
Board Member, IPS-USA, 2023-current.  
Topic Editor, Frontiers in Medicine (Research Topic: COVID-19 and Androgens), 2021.  
Editorial Board: Associate Editor of Cosmetic Dermatology Surgery, Surgical &. Cosmetic Dermatology (Journal). ISSN: 9845510, 19848773, Brazilian Society of Dermatology. 12/2019-present.

### **MEMBERSHIP IN SOCIETIES**

2015-present International Peeling Society (IPS). Active Member.  
2016-present. American Academy of Dermatology (AAD). International Fellow.  
2017-present American Society for Dermatologic Surgery (ASDS). Fellow.  
2018-present Association of Professors of Dermatology (APD). Academic Dermatologist.  
2021–present Association of Academic Cosmetic Dermatologists (AACD). Member.  
Mentor, Mentorship Committee.  
Diversity Equity and Inclusion (DEI) Committee, 2024 – present.  
Industry Relations, 2024–present.  
2022-present. American Burn Association (ABD). Member.  
2024– present Sigma Xi, The Scientific Research Honor Society. Full member.  
2008-2019 Brazilian Society of Dermatology (SBD). Title member.  
2015-2019 Brazilian Society for Dermatologic Surgery (SBCD). Member.

## **ACADEMIC PUBLICATIONS**

### **ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS**

1. **Wambier CG**, Foss-Freitas MC, Paschoal RS, Tomazini MV, Simão JC, Foss MC, Foss NT. Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. *J Am Acad Dermatol*. 2009, May; 60(5): 883-5. PMID: 19389539.
2. **Wambier CG**, Lemos FBM, Cappel MA, Bellissimo-Rodrigues F, Foss NT. Generalized Serpiginous Eruption during Immunosuppressive Treatment for Leprosy Reactive Neuritis. *PLoS Negl Trop Dis*. 2011, Dec; 5(12): e1357. PMID: 22216360.
3. **Wambier CG**, Pereira CS, Prado BP, Foss NT. Brazilian blood donation eligibility criteria for dermatologic patients. *An Bras Dermatol*. 2012, Jul; 87(4): 590-595. PMID: 22892774.
4. **Wambier CG**, Wambier SPF. Gamasoidosis illustrated--from the nest to dermoscopy. *An Bras Dermatol*. 2012, Nov; 87(6): 926-927. PMID: 23197219.
5. Zenha EM, **Wambier CG**, Novelino AL, de Andrade TA, Ferreira MA, Frade MA, Foss NT. Clinical and immunological evaluation after BCG-id vaccine in leprosy patients in a 5-year follow-up study. *J Inflamm Res*. 2012, Dec; 5(1): 125-135. PMID: 23293531.
6. **Wambier CG**, Takada MH, Foss-Freitas MC, Frade MAC, Foss MC, Foss NT. Effects of metabolic control on cutaneous findings in diabetes mellitus. *Braz J Int Med*. 2014; 1(1): 11-19.
7. **Wambier CG**, Ramalho LN, Frade MA, Foss NT. NFkB activation in cutaneous lesions of leprosy is associated with development of multibacillary infection. *J Inflamm Res*. 2014, Aug; 7(1): 133-138. PMID: 25258550.
8. **Wambier CG**, Wambier SPF. The common coffee stirrer as a perfect application tool for imiquimod. *Surg Cosmet Dermatol*. 2015; 7(1): 66-67. doi: 10.5935/scd1984-8773.2015731199
9. **Wambier CG**, Wambier SP, Furini RB, Simão JC, Frade MA, Foss NT. Factors associated with seropositivity for APGL-I among household contacts of leprosy patients. *Rev Soc Bras Med Trop*. 2016, Feb; 49(1): 83-89. PMID: 27163568.
10. **Wambier CG**, Cappel MA, Danilau Ostroski TK, Montemor Netto MR, de Farias Wambier SP, Santos de Jesus BL, Arruda E. Familial outbreak of eruptive pseudoangiomatosis with dermoscopic and histopathologic correlation. *J Am Acad Dermatol*. 2017, Feb; 76(2S1): S12-S15. PMID: 28087016.
11. **Wambier CG**, Cappel MA, Werner B, Rodrigues E, Schumacher Welling MS, Montemór Netto MR, de Farias Wambier SP. Dermoscopic diagnosis of scurvy. *J Am Acad Dermatol*. 2017, Feb; 76(2S1): S52-S54. PMID: 28087031.
12. Matnei, T, Camargo, CH, Feltrin, F, **Wambier, CG**, Baroni, E. Bob Marley's Disease: Cerebral Metastasis of Acral Melanoma. *Rev Bras Neurol*. 2017, Apr; 53(1): 42-44.

13. **Wambier CG**, Struecker TA, Durski LN, de Araújo AG, Wambier SPF, Cappel MA, Vernal S, Roselino AM. Image Gallery: A case of pemphigus vulgaris following Simulium spp. (Diptera) bites. *Br J Dermatol*. 2017, May; 176(5): e100. PMID: 28504401.
14. **Wambier CG**. Beard alopecia caused by deoxycholic acid for the treatment of submental fat. *Surg Cosmet Dermatol* 2017;9(3):259-4. doi: 10.5935/scd1984-8773.2017931037.
15. **Wambier CG**, Cappel MA, Wambier SPF. Treatment of reaction to red tattoo ink with intralesional triamcinolone. *An Bras Dermatol*. 2017 Sep-Oct;92(5):748-750. PMID: 29166529.
16. **Wambier CG**, Danilau Ostroski TK, Perillo de Farias Wambier S, Beltrame FL, Cappel MA, Piñeiro Maceira JM. Syringe lubricant and adverse reactions. *Int J Dermatol*. 2018 Jan;57(1):122-123. PMID: 29152724.
17. Vanzela TN, Bernardes-Filho F, **Wambier CG**, Faria FM, Foss NT, Frade MAC. Th17 Response of Borderline-Lepromatous Leprosy Inhibits Rash Manifestation of Dapsone Hypersensitivity Syndrome: Case Report. *Am J Dermatopathol*. 2018 Mar;40(3):205-208. PMID: 28937434.
18. **Wambier CG**, Perillo de Farias Wambier S, Pereira Soares MT, Breunig J, Cappel MA, Landau M. 5-Fluorouracil tattooing for idiopathic guttate hypomelanosis. *J Am Acad Dermatol*. 2018 Apr;78(4):e81-e82. PMID: 29102493.
19. **Wambier CG**, Wambier SPF, Pilatti LEP, Grabicoski JA, Wambier LF, Schmidt A. Prolongation of rate-corrected QT interval during phenol-croton oil peels. *J Am Acad Dermatol*. 2018 Apr;78(4):810-812. PMID: 29017839.
20. **Wambier CG**, Beltrame, FL. Air Safety and Personal Protective Equipment for Phenol–Croton Oil Peels. *Dermatol Surg*. 2018 Jul;44(7):1035-1037. PMID: 29077632.
21. **Wambier CG**. Comment on "Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary analysis of a randomized, split-body, single blinded, placebo controlled clinical trial". *J Am Acad Dermatol*. 2018 Oct;79(4):e79. PMID: 29864493.
22. **Wambier CG**, Wambier SPF, Hexsel DM. Injectable poly-L-lactic acid: instant hydration in lukewarm water bath and use of a thin needle to filter particles. *J Am Acad Dermatol*. 2018 Jul;79(1):e3-e4. PMID: 29274794.
23. **Wambier CG**, Paschoal RS, Lee KC, Dal' Forno, T. Expert survey on the efficacy, costs and healing of resurfacing procedures for facial static wrinkles. *Surg Cosm Dermatol* 2018. Dec;10(4). 367-9 doi: 10.5935/scd1984-8773.20181041297. Epub 2019 Jan 1.
24. **Wambier CG**, Hoekstra TA, Wambier SPF, Paschoal RS, Bueno Filho R, Vilar FC, Santana RC, Fonseca BAL, Frade MAC, Roselino, AM, Foss, NT. Epidermal Necrolysis: SCORTEN performance in AIDS and non-AIDS patients. *An Bras Dermatol*. 2019 Jan;94(1):17-23. PMID: 30726458.
25. **Wambier CG**, King BA. Reply to: "Comment on 'Rule of thumb: A simple tool to estimate 1% scalp surface area': Whose thumb is it anyway?" *J Am Acad Dermatol*. 2019 Dec;81(6):e185. PMID: 31470070.



26. **Wambier CG**, Lee KC, Oliveira PB, Wambier SPF, Beltrame FL. Comment on "Surgical smoke: Risk assessment and mitigation strategies" and chemical adsorption by activated carbon N95 masks. *J Am Acad Dermatol*. 2019 Apr;80(4):e79-e80. PMID: 30447321.
27. **Wambier CG**, King BA. Rethinking the classification of alopecia areata. *J Am Acad Dermatol*. 2019 Feb;80(2):e45. PMID: 30244065.
28. **Wambier CG**, Korgavkar K, Beltrame FL, Lee KC. Response to "Clinical and Histologic Evaluation of Ingenol Mebutate 0.015% Gel for the Cosmetic Improvement of Photoaged Skin". *Dermatol Surg*. 2019 Jun;45(6):857-859. PMID: 30913047.
29. **Wambier CG**, Lee KC, Bertolini TM, Rullan PP, Beltrame FL. About "Anti-aging effects of ingenol mebutate for patients with actinic keratosis" and phenol-croton oil peelings. *J Am Acad Dermatol*. 2019 Jun;80(6):e185-e186. PMID: 30716406.
30. **Wambier CG**, Neitzke IC, Lee KC, Soon SL, Rullan PP, Landau M, Simão JCL, Sterling JB, Brody HJ. Augmentation and eversion of lips without injections: the lip peel. *J Am Acad Dermatol*. 2019 May;80(5):e119-e120. PMID: 29935199.
31. **Wambier CG**, King BA. Rule of thumb: a simple tool to estimate 1% scalp surface area. *J Am Acad Dermatol*. 2019 Aug;81(2):630-631. PMID: 30682394.
32. Ortolan LS, Kim SR, Crotts S, Liu LY, Craiglow BG, Paschoal RS, **Wambier CG**, King BA, Jabbari A. IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. *J Allergy Clin Immunol*. 2019 Aug. PMID: 31470035.
33. **Wambier CG**, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. *J Am Acad Dermatol*. 2019 Sep 6. PMID: 31499158.
34. **Wambier CG**, Andrade EA, Cruz LS, Lemes BM, Carey WD, Moura BPS, Both AS, Wambier SPF, Beltrame FL. Flush technique to minimize adverse reactions from syringe lubricant (silicone oil). *J Am Acad Dermatol*. 2019 Dec;81(6):e169-e171. PMID: 30562565.
35. Lee KC, Sterling JB, **Wambier CG**, Soon SL, Rullan PP, Landau M, Brody HJ. Segmental phenol-Croton oil chemical peels for treatment of periorbital or perioral rhytides. *J Am Acad Dermatol*. 2019 Dec;81(6):e165-e166. PMID: 30528504.
36. Lemes BM, Andrade EA, Cruz LS, Minozzo BR, Carey WD, Damsky W, Miot HA, Beltrame FL, **Wambier CG**. Effect of injection solutions in the dispersion of syringe lubricant (silicone oil). *J Am Acad Dermatol*. 2020 Mar;82(3):747-749. PMID: 31369770.
37. Pompeu Raminelli AC, Rodrigues-Oliveira AF, Yokota R, Sumita JM, Oliveira-Silva D, **Wambier CG**, Bagatin E, Leonardi GR. Cutaneous absorption of tretinoin in 0.05% cream and 5% chemical peel formulas. *J Am Acad Dermatol*. March 2020. Mar 27;S0190-9622(20)30465-5. doi:10.1016/j.jaad.2020.03.045. PMID: 32229277.
38. Lee KC, Wright M, Kulesza J, Brody HJ, **Wambier CG**. Reviving the call for weight by volume standardization of trichloroacetic acid peel solutions. *J Am Acad Dermatol*. March 2020. doi:10.1016/j.jaad.2020.01.088. PMID: 32142749.

39. Justo ADS, Lemes BM, Nunes B, Antunes KA, Carletto B, Koga AY, Lipinski LC, Montemor Netto MR, Campagnoli EB, Beltrame FL, **Wambier CG**. Depth of injury of Hetter's phenol-croton oil chemical peel formula using 2 different emulsifying agents. *J Am Acad Dermatol*. 2020 Jun;82(6):1544-1546. doi: 10.1016/j.jaad.2020.02.064. Epub 2020 Mar 3. PMID: 32135207.
40. Goren A, McCoy J, **Wambier CG**, et al. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. *Dermatol Ther*. April 2020:e13365. doi:10.1111/dth.13365. PMID: 32237190.
41. **Wambier CG**, Goren A. SARS-COV-2 infection is likely to be androgen mediated. *J Am Acad Dermatol*. April 2020. doi:10.1016/j.jaad.2020.04.032. PMID: 32283245.
42. Cavanagh G, **Wambier CG**. Rational hand hygiene during the coronavirus 2019 (COVID-19) pandemic. *J Am Acad Dermatol*. 2020 Jun;82(6):e211. doi: 10.1016/j.jaad.2020.03.090. Epub 2020 Apr 5. PMID: 32268168; PMCID: PMC7130538.
43. Goren A, Vaño-Galván S, **Wambier CG**, McCoy J, Gomez-Zubiaur A, Moreno-Arrones OM, Shapiro J, Sinclair RD, Gold MH, Kovacevic M, Mesinkovska NA, Goldust M, Washenik K. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. *J Cosmet Dermatol*. 2020 Apr 16. doi: 10.1111/jocd.13443. Epub ahead of print. PMID: 32301221.
44. **Wambier CG**, Goren A, Vaño-Galván S, Ramos PM, Ossimetha A, Nau G, Herrera S, McCoy J. Androgen sensitivity gateway to COVID-19 disease severity. *Drug Dev Res*. 2020 May 15. doi: 10.1002/ddr.21688. Epub ahead of print. PMID: 32412125.
45. McCoy J, **Wambier CG**, Vano-Galvan S, Shapiro J, Sinclair R, Ramos PM, Washenik K, Andrade M, Herrera S, Goren A. Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? *J Cosmet Dermatol*. 2020 Jul;19(7):1542-1543. doi: 10.1111/jocd.13455. Epub 2020 Jun 14. PMID: 32333494; PMCID: PMC7267367.
46. **Wambier CG**, Vaño-Galván S, McCoy J, Gomez-Zubiaur A, Herrera S, Hermosa-Gelbard Á, Moreno-Arrones OM, Jiménez-Gómez N, González-Cantero A, Fonda-Pascual P, Segurado-Miravalles G, Shapiro J, Pérez-García B, Goren A. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabin sign". *J Am Acad Dermatol*. 2020 Aug;83(2):680-682. doi: 10.1016/j.jaad.2020.05.079. Epub 2020 May 22. PMID: 32446821
47. Sharma A, Surve R, Dhurat R, Sinclair R, Tan T, Zou Y, Müller Ramos P, **Wambier CG**, Verner I, Kovacevic M, Goren A. Microneedling improves minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. *J Biol Regul Homeost Agents*. 2020 Mar-Apr;34(2):659-661. doi: 10.23812/19-385-L-51. PMID: 32492993.

48. Cavanagh G, Criado PR, Pagliari C, Oliveira Carneiro FR, Simões Quaresma JA, Cappel MA, **Wambier CG**. Pernio during the COVID19 Pandemic and review of inflammation patterns and mechanisms of hypercoagulability, *JAAD Case Reports* (2020), doi: <https://doi.org/10.1016/j.jdc.2020.06.002>.
49. Justo ADS, Lemes BM, Nunes B, Antunes KA, Carletto B, Koga AY, Lipinski LC, Montemor Netto MR, Campagnoli EB, Beltrame FL, **Wambier CG**. Depth of injury of Hetter's phenol-croton oil chemical peel formula using 2 different emulsifying agents. *J Am Acad Dermatol*. 2020 Jun;82(6):1544-1546. PMID: 32135207.
50. Ramos PM, Gohad P, McCoy J, **Wambier C**, Goren A. Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants predicts response to oral minoxidil treatment for female pattern hair loss. *J Eur Acad Dermatol Venereol*. 2020 Jun 21. doi: 10.1111/jdv.16765. Epub ahead of print. PMID: 32567076.
51. Goren A, **Wambier CG**, McCoy J, Shapiro J, Vaño-Galván S, Herrera S, Glode LM. Clock genes may drive seasonal variation in SARS-CoV-2 infectivity: are we due for a second wave of COVID-19 in the fall? *J Biol Regul Homeost Agents*. 2020 Jul 16; 34(4):143:110112. doi: 10.23812/20-359-L-35. Epub ahead of print. PMID: 32700513.
52. Cadegiani FA, Goren A, **Wambier CG**. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). *Med Hypotheses*. 2020 Jul 16;143:110112. doi: 10.1016/j.mehy.2020.110112. Epub ahead of print. PMID: 32721806.
53. Ramos PM, McCoy J, **Wambier C**, Shapiro J, Vaño-Galvan S, Sinclair R, Goren A. Novel topical booster enhances follicular sulfotransferase activity in patients with androgenetic alopecia: a new strategy to improve minoxidil response. *J Eur Acad Dermatol Venereol*. 2020 Dec;34(12):e799-e800. PMID: 32432358.
54. Lim RK, **Wambier CG**, Goren A. Are night shift workers at an increased risk for COVID-19? *Med Hypotheses*. 2020 Nov;144:110147. PMID: 32758906.
55. Sterling JB, Lee KC, **Wambier CG**, Soon SL, Landau M, Rullan PP, Brody HJ. Depth Map for Face and Neck Deep Chemical Peel Resurfacing. *Dermatol Surg*. 2020 Sep;46(9):1204-1209. doi: 10.1097/DSS.0000000000002268. PMID: 31743246.
56. Cadegiani FA, **Wambier CG**, Goren A. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19. *Front Med (Lausanne)*. 2020 Jul 28;7:453. PMID: 32850920.
57. Lin EM, Goren A, **Wambier C**. Environmental Effects on Reported Infections and Death Rates of COVID-19 Across 91 Major Brazilian Cities. *High Alt Med Biol*. 2020 Dec;21(4):431-433. PMID: 33031012.
58. **Wambier CG**, Vaño-Galván S, Goren A. Reply to comment on: The Gabrin sign. *J Am Acad Dermatol*. 2021 Mar;84(3):e149-e150. PMID: 33253847.

59. MacDonald S, **Wambier CG**. Letter to the Editor on "COVID-19 Infection in Men on Testosterone Replacement Therapy". *J Sex Med*. 2021 Jun;18(6):1141-1142. PMID: 33962880.
60. Goren A, **Wambier CG**, Herrera S, McCoy J, Vaño-Galván S, Gioia F, Comeche B, Ron R, Serrano-Villar S, Ramos PM, Cadegiani FA, Kovacevic M, Tosti A, Shapiro J, Sinclair R. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. *J Eur Acad Dermatol Venereol*. 2021 Jan;35(1):e13-e15. Erratum in: *J Eur Acad Dermatol Venereol*. 2021 Jul;35(7):1595. PMID: 32977363.
61. McCoy J, **Wambier CG**, Herrera S, Vaño-Galván S, Gioia F, Comeche B, Ron R, Serrano-Villar S, Iwasiow RM, Tayeb MA, Cadegiani FA, Mesinkovska NA, Shapiro J, Sinclair R, Goren A. Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. *J Eur Acad Dermatol Venereol*. 2021 Jan;35(1):e15-e17. Erratum in: *J Eur Acad Dermatol Venereol*. 2021 Jul;35(7):1595. PMID: 32977355.
62. Gohad P, McCoy J, **Wambier C**, Kovacevic M, Situm M, Stanimirovic A, Goren A. Novel cannabidiol sunscreen protects keratinocytes and melanocytes against ultraviolet B radiation. *J Cosmet Dermatol*. 2020 Sep 16. doi: 10.1111/jocd.13693. Epub ahead of print. PMID: 32964699.
63. Cadegiani FA, Lim RK, Goren A, McCoy J, Situm M, Kovacevic M, Vaño Galván S, Sinclair R, Tosti A, **Wambier CG**. Clinical symptoms of hyperandrogenic women diagnosed with COVID-19. *J Eur Acad Dermatol Venereol*. 2020 Oct 21:e101-e104. doi: 10.1111/jdv.17004. PMID: 33089570.
64. McCoy J, Cadegiani FA, **Wambier CG**, Herrera S, Vaño-Galván S, Mesinkovska NA, Ramos PM, Shapiro J, Sinclair R, Tosti A, Goren A. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. *J Eur Acad Dermatol Venereol*. 2021 Apr;35(4):e243-e246. Erratum in: *J Eur Acad Dermatol Venereol*. 2021 Jul;35(7):1595. PMID: 33135263.
65. Landau M, Lin EM, **Wambier C**. Pustular rash after dermal filler injection should not be interpreted as Herpes Simplex infection. *Surg Cosmet Dermatology*. 2020;12(3):281-285. doi:10.5935/scd1984-8773.20201233652.
66. **Wambier CG**, McCoy J, Goren A. Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals. *J Am Acad Dermatol*. 2020 Dec;83(6):e401-e402. PMID: 32926978.
67. **Wambier CG**, Vaño-Galván S, McCoy J, Pai S, Dhurat R, Goren A. Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. *J Am Acad Dermatol*. 2020 Dec;83(6):e453-e454. PMID: 32735970.
68. Goren A, Cadegiani FA, **Wambier CG**, Vano-Galvan S, Tosti A, Shapiro J, Mesinkovska NA, Ramos PM, Sinclair R, Lupi O, Hercogova J, McCoy J. Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential

- COVID-19 vaccine booster. *Med Hypotheses*. 2021 Jan;146:110439. doi: 10.1016/j.mehy.2020.110439. Epub 2020 Nov 28. PMID: 33308937; PMCID: PMC7695567.
69. Cavanagh G, Goren A, **Wambier CG**. Scalp Neuropathy in Androgenetic Alopecia. *J Am Acad Dermatol*. 2021 Jan 18:S0190-9622(21)00182-1. doi: 10.1016/j.jaad.2021.01.034. Epub ahead of print. PMID: 33476730.
  70. Baldissera RL, Yang EJ, Schmitt JV, Lin E, de Jesus FE, E Silva Enokihara MMS, **Wambier CG**, Bagatin E. Trichloroacetic acid peels for the treatment of acanthosis nigricans. *J Am Acad Dermatol*. 2021 Jan 28:S0190-9622(21)00222-X. doi: 10.1016/j.jaad.2021.01.065. Epub ahead of print. PMID: 33516770.
  71. Chesnut WM, MacDonald S, **Wambier CG**. Could diet and exercise reduce risk of COVID-19 syndemic? *Med Hypotheses*. 2021 Mar;148:110502. doi: 10.1016/j.mehy.2021.110502. Epub 2021 Jan 24. PMID: 33529978; PMCID: PMC7830305.
  72. Cadegiani FA, Zimerman RA, Campello de Souza B, McCoy J, Pereira E Costa RA, **Wambier CG**, Goren A. The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort. *Cureus*. 2021 Jan 7;13(1):e12565. PMID: 33437562.
  73. Cadegiani FA, McCoy J, **Wambier CG**, Goren A. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). *Cureus*. 2021 Feb 1;13(2):e13047. PMID: 33643746.
  74. Cadegiani FA, McCoy J, **Wambier CG**, Vaño-Galván S, Shapiro J, Tosti A, Zimerman RA, Goren A. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. *Cureus*. 2021 Feb 22;13(2):e13492. PMID: 33633920.
  75. Cadegiani F, Lin EM, Goren A, **Wambier CG**. Potential risk for developing severe COVID-19 disease among anabolic steroid users. *BMJ Case Rep*. 2021 Feb 26;14(2):e241572. doi: 10.1136/bcr-2021-241572. PMID: 33637513; PMCID: PMC7919571.
  76. Nguyen C, Yale K, Ghigi A, Zheng K, Mesinkovska NA, **Wambier CG**, Cadegiani FA, Goren A. SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional study. *Ann Thyroid*. 2022 Mar;6:7. doi: 10.21037/aot-21-8. Epub 2021 Mar 30. PMID: 34151187
  77. Justo AS, Lemes BM, Nunes B, Antunes KA, Capote ACMO, Lipinski LC, Campagnoli EB, Emiliano J, Meurer EC, Ezemma O, Miot HA, Beltrame FL, **Wambier CG**. Characterization of the Activity of Croton tiglium Oil in Hetter's Very Heavy Phenol-Croton Oil Chemical Peels. *Dermatol Surg*. 2021; Mar 9. doi: 10.1097/DSS.0000000000002990. Epub ahead of print. PMID: 33731575.

78. MacDonald S, Matos de Oliveira A, **Wambier CG**. Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2. *Letter. J Urol*. 2021 Sep;206(3):784-785. PMID: 33998834.
79. Neitzke IC, de Grande Curi D, Lin EM, Lee KC, Soon SL, Lunardelli Bittencourt AC, Aguiar CM, Neto DJ, da Costa Filha ARC, Beltrame FL, Döll-Boscardin PM, **Wambier CG**. Translational research on the role of formula stability in Hetter's phenol-croton oil peels: Analysis of chemical studies and clinical outcomes from a randomized, double-blinded, split-face controlled trial. *J Am Acad Dermatol*. 2021 Mar;84(3):854-856. PMID: 33091468.
80. Tajalli M, **Wambier CG**. Lucio's Phenomenon. *N Engl J Med*. 2021 Apr 29;384(17):1646. doi: 10.1056/NEJMimc2025081. PMID: 33913641.
81. Gao Y, Li Y, Tan Y, Liu W, Ouaddi S, McCoy J, Kovacevic M, Situm M, Stanimirovic A, Li M, **Wambier C**, Goren A, Zou Y. Novel cannabidiol aspartame combination treatment (JW-100) significantly reduces ISGA score in atopic dermatitis: Results from a randomized double blinded placebo controlled interventional study. *J Cosmet Dermatol*. 2021 May 31. doi: 10.1111/jocd.14263. Epub ahead of print. PMID: 34056830.
82. McCoy J, Goren A, Cadegiani FA, Vaño-Galván S, Kovacevic M, Situm M, Shapiro J, Sinclair R, Tosti A, Stanimirovic A, Fonseca D, Dorner E, Onety DC, Zimerman RA, **Wambier CG**. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. *Front Med (Lausanne)*. 2021 Jul 19;8:668698. doi: 10.3389/fmed.2021.668698. PMID: 34350193.
83. Abrantes TF, Artounian KA, Falsey R, Simão JCL, Vaño-Galván S, Ferreira SB, Davis TL, Ridenour W, Goren A, Tosti A, **Wambier CG**. Time of onset and duration of post-COVID-19 acute telogen effluvium. *J Am Acad Dermatol*. 2021 Oct;85(4):975-976. doi: 10.1016/j.jaad.2021.07.021. Epub 2021 Jul 21. PMID: 34302903; PMCID: PMC8294706.
84. Cadegiani FA, Goren A, **Wambier CG**, McCoy J. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. *New Microbes New Infect*. 2021 Sep;43:100915. PMID: 34249367.
85. Peterson D, **Wambier C**, Dai F, Lampert R, Ahmad T, Yale KL, Mesinkovska NA, King B. Electrocardiogram Findings in Patients with Alopecia Areata. *Dermatol Ther (Heidelb)*. 2021 Dec;11(6):2217-2223. PMID: 34564797.
86. George EA, Castelo-Soccio L, Putterman E, Kuhn H, **Wambier C**, Qureshi A, Cho E. Influence of climate factors on pediatric alopecia areata flares in Philadelphia, Pennsylvania. *Sci Rep*. 2021 Oct 26;11(1):21034. PMID: 34702837.
87. Cavanagh G, Abrahams C, Goren A, **Wambier CG**. Seasonal and daylight saving time fluctuations in Google searches for scalp seborrheic dermatitis. *Surg Cosmet Dermatology*. 2021;13. doi:10.5935/scd1984-8773.2021130044

88. Zimerman RA, Ferrareze PAG, Cadegiani FA, **Wambier CG**, Fonseca DDN, de Souza AR, Goren A, Rotta LN, Ren Z, Thompson CE. Comparative Genomics and Characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern From Amazonas, Brazil. *Front Med (Lausanne)*. 2022 Feb 15;9:806611. doi: 10.3389/fmed.2022.806611. PMID: 35242782.
89. Gehret NL, Brooks BE, Vance TM, **Wambier CG**, Libby TJ. Impact of the COVID-19 pandemic on dermatology residency education in the United States: A cross-sectional survey. *JAAD Int*. 2022 Sep;8:134-135. doi: 10.1016/j.jdin.2022.06.003. Epub 2022 Jun 16. PMID: 35756913.
90. Lemes BM, Justo AS, Lin EM, Capote ACO, Neves AKL, Machinski I, Pereira AV, Koga AY, Lipinski LC, Beltrame FL, Miot HA, **Wambier CG**. The effects of 35% Trichloroacetic acid-Croton oil and 35% Glycolic acid-Croton oil compared to 35% Phenol-Croton oil Hetter's very heavy formula for deep chemical peel. *J Am Acad Dermatol*. 2022 Jul 18:S0190-9622(22)02350-7. doi: 10.1016/j.jaad.2022.07.023. Epub ahead of print. PMID: 35863466.
91. Gallo Marin B, Ezemma O, Frech F, Flores Servin J, Rhee B, Mulligan K, O'Connell K, Moseley I, **Wambier C**. An Analysis of Information Sources of YouTube Videos Pertaining to Tattoo Removal: Cross-sectional Study. *JMIR Dermatol* 2022;5(4):e42759. DOI: 10.2196/42759
92. **Wambier CG**, Lin E, da Costa Filha ARC, Beltrame FL, Döll-Boscardin PM, Celidonio TC, Miot HA, Hetter GP. Updates on level of evidence of clinical efficacy of facial phenol-croton oil peels and comments on history and mechanisms of action. *Int J Dermatol*. 2022 Nov 3. doi: 10.1111/ijd.16485. Epub ahead of print. PMID: 36325741.
93. Soon SL, **Wambier CG**, Rullan PR, Sterling JB, Brody HJ, Lee KC, Kreyden OP, Landau M; International Peeling Society; International Peeling Society. Phenol-Croton Oil Chemical Peeling Induces Durable Improvement of Constitutional Periorbital Dark Circles. *Dermatol Surg*. Apr 1;49(4):368-373, Epub 2023 Feb 1. doi: 10.1097/DSS.0000000000003708. PMID: 36735802.
94. Yang EJ, Wambier SPF, **Wambier CG**. Safer 1064 nm long-pulse frequency settings and safety eyewear setup to improve visualization of superficial veins. *J Am Acad Dermatol*. 2023 Apr 28:S0190-9622(23)00743-0. doi: 10.1016/j.jaad.2023.02.067. Epub ahead of print. PMID: 37121480.
95. Ragi SD, Ghanian S, Rogers N, Peterson DM, Johnson LS, **Wambier CG**. Evaluation of hair regrowth after minoxidil and dutasteride tattooing in men with androgenetic alopecia. *JAAD Int*. 2023 May 20;12:103-104. doi: 10.1016/j.jdin.2023.04.011. PMID: 37404245; PMCID: PMC10315762.
96. Paiva ML, Justo AS, Lemes BM, Capote ACO, de Castro Maymone MB, Lipinski LC, Rullan PP, Beltrame FL, Miot HA, **Wambier CG**. Skin of color repigmentation after phenol-croton oil chemical peel. *J Am Acad Dermatol*. 2023 Jul 17:S0190-9622(23)01362-2. doi: 10.1016/j.jaad.2023.06.053. Epub ahead of print. PMID: 37460064.
97. Mehta N, Huang S, Dhura R, **Wambier C**, do Nascimento Fonesca D, Little S, Goren A. Minoxidil sulfotransferase enzymatical activity in plants: A novel paradigm in increasing

- minoxidil response in androgenetic alopecia. *J Cosmet Dermatol*. 2023 Aug 28. doi: 10.1111/jocd.15980. Epub ahead of print. PMID: 37638619.
98. Paiva ML, Justo AS, Lemes BM, Capote ACMO, de Castro Maymone MB, Lipinski LC, Rullan PP, Beltrame FL, Miot HA, **Wambier CG**. Skin of color repigmentation after phenol-croton oil chemical peel. *J Am Acad Dermatol*. 2023 Nov;89(5):1068-1070. doi: 10.1016/j.jaad.2023.06.053. Epub 2023 Jul 17. PMID: 37460064.
  99. Capote, A. C. M. de O., Campos, P. M., Costa, C. C., Silva, N. R. M. da, Ferrari, P. C., Silva, M. P. B. da, Kanunfre, C. C., Carvalho, F. K. de, **Wambier, C. G.**, Andrade, E. A. de, Strangman, W. K., & Beltrame, F. L. (2023). Liquid Crystals as a Vehicle for Croton tiglium L. Oil for Deep Chemical Peel Formulations. *Brazilian Archives of Biology and Technology*, 66(spe). <https://doi.org/10.1590/1678-4324-ssbfar-2023230034>
  100. Mehta N, Huang S, Dhura R, **Wambier CG**, do Nascimento Fonesca D, Little S, Goren A. Minoxidil sulfotransferase enzymatical activity in plants: A novel paradigm in increasing minoxidil response in androgenetic alopecia. *J Cosmet Dermatol*. 2024 Jan;23(1):339-343. doi: 10.1111/jocd.15980. Epub 2023 Aug 28. PMID: 37638619.
  101. Ghanian S, Wambier SPF, **Wambier CG**. Mitigation of risk of botulinum toxin A-induced blepharoptosis with hyperconcentrated glabellar injections. *J Am Acad Dermatol*. 2023 Dec 25:S0190-9622(23)03398-4. doi: 10.1016/j.jaad.2023.12.025. Epub ahead of print. PMID: 38151057.
  102. Maymone MBC, Mirza FN, Steiner D, Ribeiro F, Landau M, Marçon C, Celidonio TC, Soon SL, **Wambier CG**; International Peeling Society. Comparative Long-Term Efficacy of Phenol-Croton Oil Chemical Peels for Persistent Melasma at Varied Croton tiglium Oil Concentrations. *J Am Acad Dermatol*. 2024 Apr 2:S0190-9622(24)00547-4. doi: 10.1016/j.jaad.2024.03.034. Epub ahead of print. PMID: 38574769.
  103. Rullan P, Lin EM, Schaut E, **Wambier CG**. Cardiac safety in full-face phenol-croton oil peels: A 22-year retrospective study. *J Am Acad Dermatol*. 2024 Jun 29:S0190-9622(24)00979-4. doi: 10.1016/j.jaad.2024.06.049. Epub ahead of print. PMID: 38950700.
  104. Jimenez-Cauhe J, Vaño-Galvan S, Mehta N, Hermosa-Gelbard A, Ortega-Quijano D, Buendia-Castaño D, Fernández-Nieto D, Porriño-Bustamante M, Saceda-Corralo D, Pindado-Ortega C, Moreno-Arrones OM, **Wambier C**, Dhura R, Lotti T, Goren A. Hair follicle sulfotransferase activity and effectiveness of oral minoxidil in androgenetic alopecia. *J Cosmet Dermatol*. 2024 Jul 22. doi: 10.1111/jocd.16473. Epub ahead of print. PMID: 39034734.
  105. Mehta N, do Nascimento Fonseca D, Dhura R, **Wambier C**, Lotti T, Goren A. A Novel Cosmetic Formulation That Rapidly Reduces Hair Shedding in Females. *J Cosmet Dermatol*. 2025 Jan;24(1):e16592. doi: 10.1111/jocd.16592. Epub 2024 Sep 26. PMID: 39327671; PMCID: PMC11743019.



106. **Wambier CG**, Mirza FN, Wambier SPF, Bertucci V, Carruthers J, Kaufman J, Martin J, Sterling JB, Brasileiro F, Marçon C, Brown AJ, Rosenberg M, Guadanhim LRS, Hexsel D. Resistance to cosmetic botulinum toxin A: A 15-patient case series across 12 sites. *JAAD Int*. 2024 Sep 28;18:5-7. doi: 10.1016/j.jdin.2024.08.021. PMID: 39553483; PMCID: PMC11564985.
107. **Wambier CG**, da Costa Filha ARC, Koga AY, Beltrame FL, Döll-Boscardin PM. Emulsifiers maximize the safety and effectiveness of deep chemical peels. *J Am Acad Dermatol*. 2025 Jan;92(1):e23-e24. doi: 10.1016/j.jaad.2024.08.067. Epub 2024 Sep 18. PMID: 39303921.
108. Coppinger AJ, **Wambier CG**. Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., "Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata". *J Am Acad Dermatol*. 2025 Jun;92(6):e203-e204. doi: 10.1016/j.jaad.2024.11.086. Epub 2025 Feb 17. PMID: 39971243.
109. Macit B, Burns L, **Wambier CG**. Repigmentation of vitiligo with 5-fluorouracil tattooing in combination with topical ruxolitinib: A case report. *JAAD Case Rep*. 2025 Feb 5;58:60-62. doi: 10.1016/j.jdcrr.2025.01.016. PMID: 40123791; PMCID: PMC11928802.
110. Kuceki G, Coppinger AJ, Ragi SD, Johnson LS, Goren A, Kalil LL, Cirino P, **Wambier CG**. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. *JAAD Int*. 2025 Feb 27;20:38-40. doi: 10.1016/j.jdin.2025.01.012. PMID: 40225275; PMCID: PMC11992372.
111. Marçon CR, Coppinger AJ, Salomão C, Alves Dos Reis V, Alves Dos Reis VN, de Menezes Gomes JL, Gianvecchio VAP, Medeiros de Aquino E, de Seixas Alves MT, Canzian M, Coelho Frenkelis Brandão SA, Fusel de Ue RR, Ribeiro F, Bageorgou F, **Wambier CG**; International Peeling Society (IPS) and São Paulo's Legal Medical Institute (IML-SP). Fatal phenol peel by an unlicensed social media practitioner: A forensic medical analysis. *J Am Acad Dermatol*. 2025 Dec;93(6):e211-e213. doi: 10.1016/j.jaad.2025.05.1461. Epub 2025 Aug 6. PMID: 40774430.

#### **PEER-REVIEWED CME / REVIEW ARTICLES**

112. **Wambier CG**, Lee KC, Soon SL, Sterling JB, Rullan PP, Landau M, Brody HJ. Advanced chemical peels: phenol-croton oil peel. *J Am Acad Dermatol*. 2019 Aug;81(2):327-336. PMID: 30550827.
113. Lee KC, **Wambier CG**, Soon SL, Sterling JB, Rullan PP, Landau M, Brody HJ. Basic chemical peels: superficial and medium-depth peels. *J Am Acad Dermatol*. 2019 Aug;81(2):313-324. PMID: 30550830.
114. **Wambier CG**, Mehta N, Goren A, Cadegiani FA. COVID-19, androgens, and androgenic alopecia. *Dermatological Rev*. 2020; Dec 23. 1-8. doi:https://doi.org/10.1002/der2.50

115. Lim RK, **Wambier CG**, Goren A. Surgical interventions for androgenetic alopecia. *Dermatological Rev.* 2021 Mar 8; doi: 10.1002/der2.66
116. Lim RK, Verner I, **Wambier CG**, Kolodchenko Y, Goren A. Nonablative radiofrequency for the treatment of androgenetic alopecia: An open-label study. *Dermatological Rev.* 2021; doi: 10.1002/der2.56
117. Dhurat R, Shukla D, Lim RK, **Wambier CG**, Goren A. Spironolactone in adolescent acne vulgaris. *Dermatol Ther.* 2021 Jan;34(1):e14680. PMID: 33326148.

#### **COMMENTARIES / LETTERS / REPLIES PUBLISHED IN PEER-REVIEWED JOURNALS**

118. **Wambier CG**, Brody HJ, Hetter GP. Comments on: A split-face comparative study between two phenol based peelings (Baker-Gordon and Hetter formulas) in the treatment of facial rhytids. *Surg Cosmet Dermatol.* 2017, Jun; 9(2): 190-1. doi: 10.5935/scd1984-8773.201792996
119. **Wambier CG**, Wambier SPF, Beltrame FL. Here is your injection: would you like with or without silicone oil? *Br J Ophthalmol* 2019. Epub 3 June. doi: 10.1136/bjophthalmol-2019-313823.
120. **Wambier CG**, Wambier SPF. "Sepsis assessment in SJS/TEN: an important point overlooked?" – Reply. *An Bras Dermatol.* 2019; 94(6):774. 10.1016/j.abd.2019.06.003. PMID: 31810799.
121. **Wambier CG**. Androgens are Key to Vulnerability. Commentary on: Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA.* 2020;10022:1-8. April 23 2020. doi: 10.1001/jama.2020.6775. PMID: 32320003.
122. **Wambier CG**. Androgen Pathway Targets and Incomplete TMPRSS2 Inhibitors list. Commentary on: Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA.* 2020;2019. April 15 2020. doi:10.1001/jama.2020.6019.
123. **Wambier CG**. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". *Int J Antibiotic Agents.* 2021 Jan;57(1):106175. PMID: 33408021.
124. **Wambier CG**, Yarak S, Miot HA. Silicone oil – systemic safety data still pending. *Dermatol Surg.* 2020 Dec;46(12):1757-1758. doi: 10.1097/DSS.0000000000002114. PMID: 31490783.
125. Ghanian S, **Wambier CG**. Letter to the Editor re: Baldassarri et al., 2021 "Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males". *EBioMedicine.* 2021 Jun;68:103425. PMID: 34134086.
126. **Wambier CG**. Refined analysis is needed particularly for ARI. Comment on: Schmidt AL, Tucker MD, Bakouny Z, et. al. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. *JAMA Netw Open.* November 14, 2021. doi: 10.1001/jamanetworkopen.2021.34330

127. Ghanian S, **Wambier CG**. Response to "Microneedling with autologous platelet-rich plasma versus microneedling with topical insulin in the treatment of postacne atrophic scars: A simultaneous split-face comparative study". *J Am Acad Dermatol*. 2021 Dec;85(6):e395-e396. PMID: 34403715.
128. **Wambier CG**, Nau GJ. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients. *Eur Urol*. 2022 Jun;81(6):e141-e142. doi: 10.1016/j.eururo.2022.01.049. Epub 2022 Feb 23. PMID: 35304000.
129. **Wambier CG**, Lee KC, Soon SL, et al. Comments on sequential Jessner's + 35% TCA peel for the treatment of facial field cancerization. *Surg Cosmet Dermatology*. 2020;12(1):87-89. doi:10.5935/scd1984-8773.20201212528
130. Abrahams C, Melo GB, **Wambier CG**. Silicone-rich syringes can cause granuloma-rich reactions in platelet-rich plasma injections. *JAAD Case Rep*. 2020 Jun 14;6(8):751-752. doi: 10.1016/j.jdc.2020.06.020. PMID: 32715070.
131. Cavanagh G, **Wambier CG**. Reply to: "Personal protective equipment recommendations based on COVID-19 route of transmission". *J Am Acad Dermatol*. 2020 Jul;83(1):e47. doi: 10.1016/j.jaad.2020.04.102. Epub 2020 Apr 25. PMID: 32344068.
132. **Wambier CG**. Reply to: "Comment on 'Androgenetic alopecia present in the majority of patients hospitalized with COVID-19'". *J Am Acad Dermatol*. 2021 Jan;84(1):e53-e54. PMID: 32860919.
133. **Wambier CG**, Tosti A. Reply to early-onset effluvium secondary to COVID-19 and body hair effluvium. *J Am Acad Dermatol*. 2021 Dec 11:S0190-9622(21)02915-7. doi: 10.1016/j.jaad.2021.11.043. Epub ahead of print. PMID: 34906663; PMCID: PMC8664718.
134. Cavanagh G, Goren A, **Wambier CG**. Circulation, sensation, and hair growth-A reply. *J Am Acad Dermatol*. 2022 Apr 23:S0190-9622(22)00692-2. doi: 10.1016/j.jaad.2022.04.027. Epub ahead of print. PMID: 35472324.
135. **Wambier CG**. Baseline severity differences? Comment on: Nickols NG, Mi Z, DeMatt E, et al. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial. *JAMA Netw Open*. 2022;5(4):e227852. doi:10.1001/jamanetworkopen.2022.7852
136. **Wambier CG**. It is time for a Randomized Placebo-controlled Trial with Androgens for COVID-19? Or more trials on antiandrogens? Comment on: Dhindsa S, Champion C, Deol E, et al. Association of Male Hypogonadism With Risk of Hospitalization for COVID-19. *JAMA Netw Open*. 2022;5(9):e2229747. doi:10.1001/jamanetworkopen.2022.7852
137. Ghanian S, Wambier SPF, Procianoy F, **Wambier CG**. About the pathways to deliver brimonidine to the Muller's muscle. *JAAD Case Rep*. 2023 Jan 7;33:7-8. doi: 10.1016/j.jdc.2022.12.014. PMID: 36785538;

138. **Wambier CG**. Commentary on picosecond Nd:YAG laser therapy for pigmentation due to lichen planus pigmentosus in a patient with skin of color. *JAAD Case Rep*. 2023 Sep 1;47:30-31. doi: 10.1016/j.jdc.2023.08.027. PMID: 38576901; PMCID: PMC10993128.
139. Coppinger AJ, Khatri S, **Wambier CG**. Comment on "5 $\alpha$ -reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study". *J Am Acad Dermatol*. 2025 Jun;92(6):e209-e210. doi: 10.1016/j.jaad.2025.01.094. Epub 2025 Feb 19. PMID: 39984056.
140. **Wambier CG**, Rullan P. Response to Marçon et al, "Fatal Phenol Peel by an Unlicensed Social Media Practitioner: A Forensic Medical Analysis". *J Am Acad Dermatol*. 2025 Dec;93(6):e215-e216. doi: 10.1016/j.jaad.2025.07.062. Epub 2025 Aug 6. PMID: 40780662.
141. Richmond A, Ray L, Truong-Balderas K, Almukhtar R, Minkis K, Eshaq M, Kuemmet T, Joo JS, Desai S, Lucas R, **Wambier C**, Boucher A, Kang B, Levin Y, Wyles S, Alam M. Pearls for dermatology resident education in cosmetic and laser procedures. *Dermatol Online J*. 2025 Apr 15;31(2). doi: 10.5070/D331265287. PMID: 40991491.

**OTHER PEER-REVIEWED PUBLICATIONS**

142. **Wambier CG** (2012). Doctoral Thesis: "The role of the activation of Nuclear Factor Kappa B (NF-kappa B) in the cutaneous expression of leprosy". [Monograph]. The Digital Library of Theses and Dissertations of the University of São Paulo, 17 (85).

## **BOOKS AND BOOK CHAPTERS**

1. **Wambier CG.** (2016). Acne and Acne Scars (Acne e Cicatrizes de Acne). In Ayres EL, Sandoval, MHL (Ed.), *Toxina Botulínica na Dermatologia* (pp. 365-376). Rio de Janeiro: Guanabara Koogan.
2. **Wambier CG,** Freitas, FP. (2017). Combining phenol-croton oil peeling. In Issa, M.C., Tamura, B. (Ed.), *Clinical Approach and Procedures in Cosmetic Dermatology* (pp. 802-843). Heidelberg: Springer.
3. **Wambier CG.** (2017). My personal experience with chemical peels. In Issa, MCA, Tamura, B. (Ed.), *Chemical and Physical Procedures, Clinical Approaches and Procedures in Cosmetic Dermatology*. (pp. 200-213). Heidelberg: Springer.
4. Simao JCL, **Wambier CG.** (2017). Combining Superficial Chemical Peels. In Issa, MCA, Tamura, B. (Ed.), *Chemical and Physical Procedures, Clinical Approaches and Procedures in Cosmetic Dermatology*. (pp. 222-245). Heidelberg: Springer.
5. **Wambier CG.** (2017). Pyruvic Acid Peels. In Issa MCA, Tamura B. (Ed.), *Clinical Approach and Procedures in Cosmetic Dermatology* (pp. 751-777). Heidelberg: Springer.
6. **Wambier CG.** (2019). Chemical peels in ethnic skin: Latin American Skin. In Sarkar, R, Roberts, W (Ed.), *Chemical Peels- a Global Perspective* (pp. 1-12). New Delhi: Jaypee Brothers Medical Publisher (P) LTD.
7. **Wambier CG,** Hexasel, DM. (2019). Definition and classification of chemical peels. In Sarkar, R, Lweis, W (Ed.), *Chemical Peels- a Global Perspective* (pp. 1-15). New Delhi: Jaypee Brothers Medical Publisher (P) LTD.
8. **Wambier CG,** Brody, H. (2020). Classification of Chemical Peels. In Costa, A (Ed.), *Minimally Invasive Aesthetic Procedures for Dermatologists and Plastic Surgeons* (pp. 1-12). Atlanta: Springer Nature. ISBN 978-3-319-78264-5
9. Ayres F, **Wambier CG** (2020). Phenol-Croton oil peels. In Costa, A (Ed.), *Minimally Invasive Aesthetic Procedures for Dermatologists and Plastic Surgeons* (pp. 50-59). Atlanta: Springer Nature. ISBN 978-3-319-78264-5.
10. **Wambier CG.** (2020) Segmental Phenol Croton Oil Peels for Brow Lifting, Eyelid Tightening, and Lip Eversion. In Obagi, S. (Ed.) *Procedures in Cosmetic Dermatology Series: Chemical Peels, 3rd ed. London, UK. Elsevier LTD, Printed book and E-book ISBN 9780323653893, 9780323709651.*
11. **Wambier CG.** (2021) Safety considerations in Phenol-Croton oil peels. In Steiner D. (Ed) *Practical Manual of Chemical Peels, 1<sup>st</sup> ed.* Sao Paulo, Brazil. DiLivros. ISBN 978-65-86143-01-0
12. **Wambier CG.** (2021) Foreword. In Steiner D. (Ed) *Practical Manual of Chemical Peels, 1<sup>st</sup> ed.* Sao Paulo, Brazil. DiLivros. ISBN 978-65-86143-01-0

**OTHER NON-PEER REVIEWED PUBLICATIONS (PREPRINT)**

1. **Wambier CG**, Goren A, Ossimetha A, Nau J, Qureshi A. Androgen-driven COVID-19 pandemic theory. Pre-print March 2020. doi: 10.13140/RG.2.2.21254.11848
2. Cadegiani FA, **Wambier CG**, Goren A. An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial. medRxiv. January 2020:2020.10.05.20206870. doi:10.1101/2020.10.05.20206870
3. **Wambier CG**, Lim R, Goren A. Horas non numero nisi aestivas - timing the impacts of "Daylight Saving" shifts in COVID-19 reported cases. Pre-printed Oct 2020. DOI: 10.13140/RG.2.2.13011.60969
4. Cadegiani FA, do Nascimento Fonseca D, McCoy J, et al. Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial. medRxiv. January 2021:2021.06.22.21259318. doi:10.1101/2021.06.22.21259318
5. Cadegiani FA, Goren A, **Wambier CG**, Zimmerman RA. Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial). medRxiv. January 2021:2021.07.24.21261047. doi:10.1101/2021.07.24.21261047
6. Cadegiani FA, do Nascimento Fonseca D, do Nascimento Correia M, et al. Proxalutamide Improves Lung Injury in Hospitalized COVID-19 Patients – an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial. medRxiv. January 2021:2021.07.01.21259656. doi:10.1101/2021.07.01.21259656

**ABSTRACTS**

1. **Wambier CG**, Foss NT, Souza CS. Levels of plasma and urinary porphyrins of patients undergoing photodynamic therapy with hematoporphyrin derivative. International Symposium for Scientific Initiation 2003. 2003, Jul; 11(1): 13-14.
2. Salathiel ASM, Formighieri PF, Santos AFJ, Grecco Filho AS, **Wambier CG**, Sampaio PRA, Ferrioli E, Moriguti JC. Pilot project: Profile of the doctor of the elderly. Livro de Resumos III Congresso Paulista de Geriatria e Gerontologia. 2003, Jul; 1(S1): 13.
3. **Wambier CG**, Misiara FP, Almeida SL, Petean FC, Foss NT. Trychophyton rubrum folliculitis and immunosuppression. An Bras Dermatol. 2006, Sep; 81(1): S236-S236.
4. **Wambier CG**, Frade MAC, Takada MH, Foss-Freitas MC, Foss MC, Foss NT. Relationship between cutaneous manifestations and metabolic control in diabetes patients. World Congress of Dermatology Book of Abstracts. 2007, May; 1(1): 534-535.
5. Paschoal RS, **Wambier CG**, Roselino AM, Foss NT. Analysis of 27 cases of SSJ/TEN in a University Hospital. An Bras Dermatol. 2007, Sep; 82(1): 197.
6. **Wambier CG**, Frade MAC, Foss-Freitas MC, Foss NT. Relationship between cutaneous manifestations and metabolic control in diabetes patients. An Bras Dermatol. 2007, Sep; 82(1): 202.
7. **Wambier CG**, Paschoal RS, Roselino AM, Foss NT. Analysis of the applicability of SCORTEN: prognosis scale for Stevens-Johnson syndrome and Toxic Epidermal Necrolysis in a University Hospital. An Bras Dermatol. 2007, Sep; 82(S1): 173-174.
8. **Wambier CG**, Foss-Feitas, MC, Paschoal RS, Tomazini MV, Simao JC, Foss NT, Foss MC. Hypoglycemia after anti-TNF therapy (etanercept) in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. XXVI RADLA. 2008, Jun; 26(S1): 175-175.
9. **Wambier CG**, Foss-Freitas MC, Paschoal RS, Tomazini MV, Simão JC, Foss MC, Foss NT. Hypoglycemia after therapy with anti-TNF (etanercept) in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. Arq Bras Endoc Metabol. 2008, Jul; 52(1): 175-175.
10. **Wambier CG**, Foss-Freitas MC, Takada MH, Frade MAC, Foss NT. Metabolic Control and skin manifestations in diabetes mellitus. Arq Bras Endoc Metabol. 2008, Jul; 52(S1): 217-217.
11. **Wambier CG**, Domiciano CJ, Oliveira HF, Farina Jr JA, Frade MAC. Treatment of keloids of the external ear with excision and adjuvant orthovoltage radiotherapy. Caderno de Resumos do Congresso de Cirurgia Dermatológica 2008 Jul; 1(1): 12-12.
12. Tomazini MV, **Wambier CG**, Brito MMC, Frade MAC. Evaluation of dermatology division consults for inpatients in a university hospital. Poster Abstracts for the 13th RADESP. 2008, Sep; 13(1): 34-34.
13. Wambier SPF, Vicente LM, Rodrigues MLV, Paula JS, **Wambier CG**. Lacrimal film and ocular surface dysfunction in patients with metabolic syndrome. Arquivos Brasileiros de Oftalmologia. 2008, Jul; 71(S1): 30-40.
14. Yamashiro K, Correa NC, Sabe FF, Meireles ALB, Oshiro DK, Molina M, **Wambier CG**, Frade MAC. Retrospective study of cases of leprosy examined by the student League of Leprosy "Luiz Marino Bechelli" from 1998 to 2007. Revista Medicina. 2009, Dec; 42(S1): 13-13.
15. Correa NC, **Wambier CG**, Simão JC, Furini RB, Foss NT. Leprosy treatment: an evaluation of substitutive therapy to standard multi-drug regimen. Hansenologia Internationalis. 2010, Jul; 35(1): 67-67.



16. Correa NC, **Wambier CG**, Simão JC, Furini RB, Foss NT. Change in liver function tests associated with leprosy multi-drug therapy. *Hansenologia Internationalis*. 2010, Jul; 35(1): 38.
17. **Wambier CG**, Takada MH, Foss-Freitas MC, Frade MAC, Foss MC, Foss NT. Metabolic Control and Seborrheic Dermatitis in Diabetic Patients. *Revista Medicina*. 2010, Sep; 43(S1): 35-35.
18. **Wambier CG**, Graça F, Bueno Filho R, Maitto FB, Foss NT. Exuberant Larva Currens: A manifestation of disseminated strongyloidiasis during the treatment of leprosy reaction. *Revista Medicina*. 2010, Sep; 43(S1): 44-45.
19. Picado HR, Bellissimo-Rodrigues F, **Wambier CG**. Vitiligo induced by imiquimod: review and case report. *Revista Medicina*. 2012, Dec; 45(S1): 8-8.
20. **Wambier CG**. Dermatologic treatments with microinfusion of drugs into the skin with tattoo equipment: Teaser series. *J Am Acad Dermatol*. 2018 Oct;79, S1(3), AB103.
21. Ghanian S, **Wambier CG**. Minoxidil and dutasteride drug tattooing for male androgenetic alopecia. Poster selected for Oral presentation May 07, 2021. 2021 Society for Investigative Dermatology Virtual Annual Meeting. Abstract LB792. Available in: <http://2021sidvirtualmeeting.org/wp-content/uploads/2021/05/SID-2021-Virtual-Meeting-LB-Abstract-Booklet-FINAL.pdf>
22. Paiva ML, Miot HA, Beltrame FL, Justo AS, Harrington DT, Hunter MA, **Wambier CG**. Translational research in Skin of Color Spontaneous Repigmentation of Post-Chemical Burn Leucoderma. *J Burn Care*. 2022 Apr 2022;43, S1(213), AB815.
23. Capote ACO, Justo AS, Wambier CG, Beltrame FL. Evaluation of shelf life of the stock solution of croton tiglium oil L. utilized in Hetter's deep chemical peeling. Banner at the Congresso CFF de Ciencias Farmacêuticas Edição Natal – RN – Brazil. October 28 2023.
24. Capote ACO, Justo AS, Wambier CG, Beltrame FL. Effects of Croton tiglium oil as deep chemical peeling in skin rejuvenation. 14<sup>th</sup> International Congress of Pharmaceutical Sciences in Ribeirao Preto – SP – Brazil. November 15 2023.

## **SCHOLARLY WORK PUBLISHED IN OTHER MEDIA**

### PEER-REVIEWED

1. **Wambier CG**, Foss NT, Souza CS (July, 2003). *Plasma and Urinary Porphyrin levels in patients undergoing photodynamic therapy with hematoporphyrin derivative*. Poster presented at: 11th International Symposium for Scientific Initiation; Ribeirão Preto, Brazil.
2. Almeida, S.L, Misiara, F.P., Ghedini, A.P., Oliveira, F.R., **Wambier, C.G.**, Louzada JR, P. (July, 2006). *Systemic amyloidosis and multiple myeloma: atypical presentation in a young patient in a rheumatology clinic*. Poster presented at: Brazilian Rheumatology Meeting 2006; Sao Paulo, Brazil.
3. **Wambier CG**. (July 2007) "*Relationship between cutaneous manifestations and metabolic control in diabetic patients.*" Oral presentation at: 21<sup>st</sup> World Congress of Dermatology (WCD), Buenos Aires, Argentina.
4. Ostroski TKD, Young Blood MR, Lopes LC, Wambier SPF, **Wambier CG**. (April, 2016). *The Association of Papilomatosis Confluens and Reticulated of Gougerot Carteaud and Ross Syndrome in the same patient*. Poster presented at: 24th South Brazilian Dermatology Meeting; Curitiba, Brazil.
5. Ostroski TKD, Cappel MA, Arruda E, Montemor-Netto MR, **Wambier CG**. (April, 2016). *Eruptive Pseudoangiomatosis Outbreak in Brazil - Dermoscopy, Histology and Viral Research Findings*. Poster presented at: 24th South Brazilian Dermatology Meeting; Curitiba, Brazil.
6. Barszcz, K, Cappel, MA, Ferreira, LM, Frade MAC, Faria FM, Wambier SPF, **Wambier CG** (April, 2016). A report of 2 cases where drug-induced hypersensitivity syndrome spares leprosy lesions of multibacillary and paucibacillary cases. Poster presented at: 24th South-Brazilian Dermatology Meeting; Curitiba, Brazil.
7. Kuhn CA, Ostroski TKD, Arruda E, Montemor-Netto MR, **Wambier CG**. (June, 2016). *Eruptive Pseudoangiomatosis Outbreak in Brazil - Dermoscopy, Histology and Viral Research Findings*. Poster presented at: XXXIV Reunião Anual dos Dermatologistas Latino-Americanos (RADLA) (Latin-American Meeting); São Paulo, Brazil.
8. Barszcz K, **Wambier CG**, Frade MAC, Faria FM, Wambier SPF. (June, 2016). *DIHS spares leprosy lesions in multibacillary and paucibacillary cases*. Poster presented at: XXXIV Reunião Anual dos Dermatologistas Latino-Americanos (RADLA) - (Latin-American Meeting); Sao Paulo, Brazil.
9. Geise GCA, Machado PC, Taques L, **Wambier CG**, Campagnoli EB. (September, 2016) *Pemphigus Vulgaris in a young adult – case report*. Poster and oral presentation at the 21<sup>st</sup> International Meeting of Dentistry, Brazilian Association of Dentistry, Ponta Grossa, Brazil.
10. **Wambier, CG**, Ostroski, TKD, Lopes LC, Young Blood, MR, Wambier SPF, Camargo, CH. (September, 2016). *The Association of Papilomatosis Confluens and Reticulated of Gougerot Carteaud and Ross Syndrome in the same patient*. Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.
11. Ostroski TKD, Cappel MA, Arruda E, Montemor-Netto MR, **Wambier CG**. (September, 2016). *Eruptive Pseudoangiomatosis Outbreak in Brazil - Dermoscopy, Histology and Viral*

*Research Findings* Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.

12. **Wambier CG**, Hoekstra TA, Bueno Filho R, Vilar FC (September, 2016). *Review of 25 years of cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a University Hospital*. Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.
13. Barszcz K, Montemor Netto MR, Rodrigues E., Schumacher MS, Cappel MA, Wambier SPF, **Wambier CG** (September, 2016). *Scurvy: The Correlation of Clinic, Dermoscopic and Histopathological findings*. Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.
14. Barszcz K, Bernardes Filho F, Frade MAC, Faria FM, **Wambier CG** (September, 2016). *DIHS spares leprosy lesions in multibacillary and paucibacillary cases*. Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.
15. **Wambier CG**. Dermatologic treatments with microinfusion of drugs through the skin: Teaser series. E-poster presented at: 2018 AAD Annual Meeting. San Diego, CA, USA.
16. **Wambier CG**, Lee KC, Soon SL, Sterling JB, Brody HJ. Augmentation and eversion of lips without injections: the lip peel. Poster presented at: ASDS meeting 2018. Phoenix, AZ, USA.

## NON-PEER-REVIEWED

1. **Wambier CG**, King BA. JAK inhibitors for Atopic Dermatitis – STAT!. The Dermatologist. 2018. Nov. 17-9. (Feature Cover).
2. **Wambier CG**. Experts Insights in Derm: Chemical Peels 101: Q&A With Dr Wambier. The Dermatologist. 2020. Mar. Available online at [www.the-dermatologist.com/news/chemical-peels-101-ga-dr-wambier](http://www.the-dermatologist.com/news/chemical-peels-101-ga-dr-wambier)
3. **Wambier CG**. What androgens might have to do with COVID-19. The Dermatologist. 2020. Apr. Available online at [www.the-dermatologist.com/news/dr-wambier-what-androgens-might-have-do-covid-19](http://www.the-dermatologist.com/news/dr-wambier-what-androgens-might-have-do-covid-19)
4. **Wambier CG**. Conversations on COVID: Exploring genetic links to COVID-19 severity. Q&A Brown University 2020. Apr. Available online at [www.brown.edu/news/2020-04-07/androgen](http://www.brown.edu/news/2020-04-07/androgen)

## INFORMATIONAL MEDIA

Newspaper      What is psoriasis? *Jornal da Manhã - Coluna Saúde*; Wambier, CG. (2012, March 11). Burns demand specific care. *Jornal da Manhã - Coluna Saúde*; Kruger, A.C., Wambier, C.G. (2012, April 15). The main causes of acne. *Jornal da Manhã - Coluna Saúde*; Kruger, A.C., Wambier, C.G. (2012, June 10). Daily skin care during winter. *Cuidados com a pele no inverno*; Kruger, A.C., Wambier, C.G. (2012, July 08). Health Column, Dermatology, for regional newspaper: KRUGER, A.C., WAMBIER C.G. (2012, September 16). 20 years of Botox cosmetic treatments. *Jornal da Manhã - Coluna Saúde*. 2011-2012

Cabana, E. Peeling the way to augmented lips. *Dermatology Times*, October 2019 (Vol. 40, No. 10). Available online at: <https://www.dermatologytimes.com/view/peeling-way-augmented-lips>

The Brown Daily Herald, April 23, 2020 "Brown assistant professor co-leads ongoing investigation on link between hair-loss causing hormones, COVID-19" available online at: [www.browndailyherald.com/2020/04/23/brown-assistant-professor-co-leads-ongoing-investigation-link-hair-loss-causing-hormones-covid-19/](http://www.browndailyherald.com/2020/04/23/brown-assistant-professor-co-leads-ongoing-investigation-link-hair-loss-causing-hormones-covid-19/)

The Daily Telegraph, June 4 2020 "Bald men at higher risk of severe case of Covid-19, research finds" available online: <https://www.telegraph.co.uk/global-health/science-and-disease/bald-men-higher-risk-severe-case-covid-19-research-finds/>

Magazine      Science Magazine, Jun 3 2020. Why coronavirus hits men harder: sex hormones offer clues. Available online: <https://www.sciencemag.org/news/2020/06/why-coronavirus-hits-men-harder-sex-hormones-offer-clues>

Forbes Magazine: Study Suggests Bald Men Could Be More At Risk For Severe Coronavirus, But More Research Is Needed, available online at:  
<https://www.forbes.com/sites/marlamilling/2020/06/06/bald-men-at-higher-risk-of-severe-coronavirus-symptoms/#3d4023b629e4>

International TV Interviews about skin cancer, skin checks, and photodynamic therapy during "Orange December" at national television (Rede Globo), 2016-2017.

International TV Interview about COVID-19 gender factor Voice of America - Russian Service 2020

International Radio Interview about COVID-19 and baldness. Radio Berkshire, BBC, London, June 2020.

#### **PEER REVIEWER – JOURNAL SERVICE**

2011-2019	Anais Brasileiros de Dermatologia (ABD)
2011-2018	International Journal of Dermatology (IJD)
2012-2024	PLOS ONE
2012-2018	PLOS NTD
2012-2018	Clinical and Experimental Dermatology (CED)
2017-	Journal of the American Academy of Dermatology (JAAD)
2019-2021	Dermatologic Therapy
2019-	Surgical and Cosmetic Dermatology (SCD)
2019-	Journal of Cosmetic Dermatology (JCD)
2020-	Journal of the European Academy of Dermatology and Venereology (JEADV)
2024-	JAMA Dermatology

## **INVITED PRESENTATIONS**

### INTERNATIONAL

1. 33<sup>rd</sup> Annual Meeting of Latin-American Dermatologists (RADLA). "FACIAL PROCEDURES: BOTULINUM TOXIN, PEELINGS, FILLERS: Modified classical peelings and their combination with newer techniques." Lima, Peru, 2015.
2. 33<sup>rd</sup> Annual Meeting of Latin-American Dermatologists (RADLA). "International Symposium of Experts in LASER treatments "Problems of always, today solutions": REVLITE". Lima, Peru, 2015.
3. 2<sup>nd</sup> Meeting of Cynosure, Palomar, Conbio "Revlite", Sao Paulo, Brazil, 2015.
4. 34<sup>th</sup> Annual Meeting of Latin-American Dermatologists (RADLA). "Revlite". Sao Paulo, Brazil, 2016.
5. PeruDerm "Revlite: Melasma and Laser Peel - Live Procedure," Lima, Peru, 2016.
6. PeruDerm "Microinfusion of Medications through the skin - Live Procedure". Lima, Peru, 2016.
7. PeruDerm "Intensive treatment for melasma and facial melanosis: association of topical and oral medications, LASER and peelings". Lima, Peru, 2016.
8. International day, American Academy of Dermatology (AAD) Annual Meeting 2017. "Using Hetter's Deep Peeling formulas effectively and easily." International Peeling Society Session. Orlando, Florida, USA, 2017.
9. 22<sup>nd</sup> Congreso del Colegio Ibero Latinoamericano de Dermatología (CILAD 2018). "Pearls in Deep Chemical Peels". Sao Paulo, Brazil, 2018.
10. 24<sup>th</sup> World Congress of Dermatology (WCD). "Chemical peels – why dermatologists must use them?". Milan, Italy, 2019.
11. 24<sup>th</sup> World Congress of Dermatology (WCD). "Chemical Peels in Skin of Color". Milan, Italy, 2019.
12. 37<sup>th</sup> Annual Meeting of Latin-American Dermatologists (RADLA). "Avoiding silicone oil escape in Botulinum Toxin injections." In the session "Everything you have to know about Botulinum Toxin". Buenos Aires, Argentina, 2019.
13. 14<sup>th</sup> World Congress of Cosmetic Dermatology. "The Burden of pigmentary disorders", Lima, Peru, 2019.
14. 14<sup>th</sup> World Congress of Cosmetic Dermatology. "Tattoo: from pigment to active drugs", Lima, Peru, 2019.
15. 14<sup>th</sup> World Congress of Cosmetic Dermatology. "Melasma and PIH- Pearls with low fluency Q-switched Nd-Yag lasers," Lima, Peru, 2019.
16. 14<sup>th</sup> World Congress of Cosmetic Dermatology. "Photoaging and medical dermatology: more characteristics in common than differences," Lima, Peru, 2019.
17. Aesthetics 2019 – Invited International Faculty. "Mastering Phenol-croton oil indications: Lip Peel." New Delhi, India, 2019.
18. Aesthetics 2019 – Invited International Faculty. "Hands on & Master Classes - Tips on Tattooing: from art to active drugs." New Delhi, India, 2019.

19. Aesthetics 2019 – Invited International Faculty. "Colors and shades of retinoic acid peels in daily practice." New Delhi, India, 2019.
20. Aesthetics 2019 – Invited International Faculty. "Low Fluency Q-Switched Nd-YAG Laser - optimizing technique for melasma." New Delhi, India, 2019.
21. Leader Healthcare, – Cynosure Inc sponsored event. "Innovation of short pulsed laser in aesthetic procedure." Delhi, India, 2019.
22. Leader Healthcare, – Cynosure Inc sponsored event. "Innovation of short pulsed laser in aesthetic procedure." Mumbai, India, 2019.
23. 28<sup>th</sup> European Academy of Dermatology and Venerology meeting (EADV). "Idiopathic guttate hypomelanosis: From etiology to treatment." Madrid, Spain, 2019.
24. Global Virtual Aesthetics Summit (GVAS2019). "Deep peels: formulas and indications," Worldwide, Online Meeting, 2019.
25. Master Injection Academy – Invited International Faculty. "Lip Peel – augmentation and eversion without fillers." Sao Paulo, Brazil, 2019.
26. Master Injection Academy – Invited International Faculty. "Chemical Peels in the age of injectables." Sao Paulo, Brazil, 2019.
27. Congreso del Colegio Ibero Latinoamericano de Dermatología (CILAD Virtual). "Androgenetic alopecia and COVID-19" – 2020.
28. Global Hair Loss Summit (GHLS) 2020 – Keynote Lecture: Androgenetic Alopecia and COVID-19. Dec 2020.
29. 13<sup>th</sup> 5-Continent Congress (5CCs) – Lecture "Phenol croton oil peels: Scientific Update" on the session "What chemical peels can do for you", International Peeling Society Session, Online Event, September 5, 2021.
30. 13<sup>th</sup> 5-Continent Congress (5CCs) – What chemical peels can do for you", International Peeling Society Session - Questions and Answers, online live panel, September 5, 2021.
31. Brazilian National Academy of Medicine. The frontiers of medicine in 2021. Lecture: "Vulnerabilidade Andr gena na COVID-19 – Uma nova fronteira terap utica", ANM, Rio de Janeiro, Brazil, Aug 19, 2021.
32. International Peeling Society Webinar. "Dissecting the phenol-croton oil formula: what we know and what we don't know", Nov 30 2021, Germany.
33. 1<sup>st</sup> What Is New Now (WINN-DERM). "What's new in chemical peels", Sao Paulo, 25 Jun 2022.
34. 23<sup>rd</sup> Congreso del Colegio Ibero Latinoamericano de Dermatología (CILAD 2022). "Reasons to include deep peels in office procedures" Madrid, Spain, 29 Jun 2022.
35. 23<sup>rd</sup> Congreso del Colegio Ibero Latinoamericano de Dermatología (CILAD 2022). "Art and Technique of Peeling" Madrid, Spain, 02 Jul 2022 – International Peeling Society Session.
36. 23<sup>rd</sup> Congreso del Colegio Ibero Latinoamericano de Dermatología (CILAD 2022). "The Brazilian Lip Peel" Madrid, Spain, 02 Jul 2022– International Peeling Society Session.
37. World Congress of Hair Research 2022 (Hair 2022 Congress- WCHR). "Androgens and COVID-19 – the current evidence". Melbourne, Australia. Nov 19 2022.
38. 21st Aesthetic & Anti-aging World Congress (AMWC 2023), Monaco, March 30 - April 01 2023. Session: Chemical Peels. Lecture: Brazilian Lip Peel.
39. 5<sup>th</sup> Annual Trichology Update Conference, Mumbai, India, June 9–11, 2023. Session: Deciphering the complexities of Alopecia Areata. Lecture: How to incorporate JAK inhibitor into clinical practice and which one works best?

40. 5<sup>th</sup> Annual Trichology Update Conference, Mumbai, India, June 9–11, 2023. Session: Pharmacology in hair. Lecture: Side effects of drugs used in Trichology – How do I manage? 5aRi.
41. 5<sup>th</sup> Annual Trichology Update Conference, Mumbai, India, June 9–11, 2023. Session: Therapeutic pearls in trichology. Lecture: Scalp drug delivery
42. 25<sup>th</sup> World Congress of Dermatology. Session: Chemical Peels. "Repigmentation of the skin post deep peels in skin of color." International League of Dermatology Societies (ILDS). Suntec, Singapore, July 3, 2023.
43. 25<sup>th</sup> World Congress of Dermatology. Session: Chemical Peels. "Deep chemical peels: my favorite deep peels and how I do it." International League of Dermatology Societies (ILDS). Suntec, Singapore, July 4, 2023.
44. Tofacitinib Opportunities & Perspective – TOP Symposium (International Webinar). "JAK inhibitors for Licensed Indications & Beyond". Mumbai, India, September 24, 2023.
45. Tofacitinib Opportunities & Perspective – TOP Symposium (International Webinar). "Optimizing Best Practices for JAK inhibitors in the Indian & International Context". Mumbai, India, September 24, 2023.
46. 42<sup>nd</sup> Annual Meeting of the International Society for Dermatologic & Aesthetic Surgery. Session 2 AESTHETIC Chemical Peelings. "Best Peeling combinations". Rio de Janeiro, Brazil. September 28, 2023.
47. 42<sup>nd</sup> Annual Meeting of the International Society for Dermatologic & Aesthetic Surgery. Session 16 – HAIR RESTORATION Medical-Minimally-Invasive-Surgical. "Drug tattooing for Androgenetic Alopecia". Rio de Janeiro, Brazil. September 30, 2023.
48. 32<sup>nd</sup> European Academy of Dermatology and Venerology meeting (EADV). Session: Peeling. "Blepharopeeling with phenol-croton oil". Berlin, Germany, October 14, 2023.
49. 32<sup>nd</sup> European Academy of Dermatology and Venerology meeting (EADV). Session: IPS – International Peeling Society: "Chemical Peelings – past, present and future"- "Zorro Mask Phenol-Croton oil Peel". Berlin, Germany, October 14, 2023.
50. Chemical Peeling Conference. "Phenol-croton oil peeling" November 17, 2023, Praxisklinik Kreyden, Basel, Switzerland.
51. Chemical Peeling Conference. "Periorbital peeling including chemical blepharoplasty" November 17, 2023, Praxisklinik Kreyden, Basel, Switzerland.
52. 10<sup>th</sup> PeruDerm. Block 4 - Peeling and Mesotherapy. "Updates in phenol-croton oil formulas". Lima, Peru. November 23, 2023.
53. 10<sup>th</sup> PeruDerm. Block 4 - Peeling and Mesotherapy. "Peels for periocular area". Lima, Peru. November 23, 2023.
54. 10<sup>th</sup> PeruDerm. Block 5 - News in Injectables. "Botulinum toxin A: Improvement of dilutions and technique". Lima, Peru. November 25, 2023.
55. 25<sup>th</sup> International Master Course on Aging Science (IMCAS) World Congress 2024, Paris, February 1<sup>st</sup>, 2024, "PRP versus insulin for acne scars".
56. 25<sup>th</sup> International Master Course on Aging Science (IMCAS) World Congress 2024, Paris, February 1<sup>st</sup>, 2024, "Safety and prevention - Checkups for peels".
57. 25<sup>th</sup> International Master Course on Aging Science (IMCAS) World Congress 2024, Paris, February 2<sup>nd</sup>, 2024, "Medical Hair Restoration".



58. 25<sup>th</sup> International Master Course on Aging Science (IMCAS) World Congress 2024, Paris, February 3<sup>rd</sup>, 2024, "Minoxidil tattooing".
59. 22<sup>nd</sup> Aesthetic & Anti-aging World Congress (AMWC 2024), Monaco, March 28, 2024. Session: Chemical Peeling Experts on Hot Peeling Topics. Lecture: "What's the role of Deep Peeling in the treatment of Melasma".
60. 1<sup>st</sup> Sinmelasma June 7-9, 2024 Bogotá, Colombia - International Society of Melasma and other pigmentary disorders. "Are superficial peelings useful in the treatment of Melasma?"
61. 1<sup>st</sup> Sinmelasma June 7-9, 2024 Bogotá, Colombia - International Society of Melasma and other pigmentary disorders. "Can phenol peeling cure melasma?"
62. 1<sup>st</sup> International Master Course on Aging Science (IMCAS) Americas 2024, Sao Paulo, April 26, 2024. "Minoxidil and dutasteride mesotherapy or drug tattooing".
63. 1<sup>st</sup> International Master Course on Aging Science (IMCAS) Americas 2024, Sao Paulo, April 27, 2024. "Updates in phenol-croton oil peels".
64. IMCAS Press Conference. Biohacking and Regenerative Medicine: Toward a Revolution in Aging and Longevity, Paris, France.
65. 26<sup>th</sup> International Master Course on Aging Science (IMCAS) World Congress 2025, Paris, January 31, 2025, "Scalp Neuropathy in Androgenetic Alopecia".
66. 26<sup>th</sup> International Master Course on Aging Science (IMCAS) World Congress 2025, Paris, January 31, 2025, "Phenol-croton oil peels for melasma".
67. 26<sup>th</sup> International Master Course on Aging Science (IMCAS) World Congress 2025, Paris, January 31, 2025, "Reversing epigenetic aging".
68. 26<sup>th</sup> International Master Course on Aging Science (IMCAS) World Congress 2025, Paris, February 1, 2025, "Melasma and peelings".
69. 23<sup>rd</sup> Aesthetic & Anti-aging World Congress (AMWC 2025), Monaco, March 29, 2025. Session: The best chemical peeling protocols – step by step for optimal results. Lecture: "Safety and pain management in phenol-croton oil peels".
70. 2<sup>nd</sup> International Master Course on Aging Science (IMCAS) Americas 2025, Sao Paulo, April 11-13, 2024. "Debate 1: Phenol for dark skin types – Crazy choice or not?".
71. 2<sup>nd</sup> International Master Course on Aging Science (IMCAS) Americas 2025, Sao Paulo, April 11-13, 2024. "Battle: Phenol or laser resurfacing".
72. 2<sup>nd</sup> International Master Course on Aging Science (IMCAS) Americas 2025, Sao Paulo, April 11-13, 2024. "Safety of targeting aging with rapamycin: What to monitor in mTOR biohacking?".

## NATIONAL

1. 69<sup>th</sup> Annual Meeting of the Brazilian Society of Dermatology (SBD). "Therapeutic Pearls in Facial Rejuvenation: Phenol Peels and its Variations," Recife, Brazil, 2014.
2. 69<sup>th</sup> Annual Meeting of the Brazilian Society of Dermatology (SBD). "Biomolecular Cosmeceuticals," Recife, Brazil, 2014.
3. Annual Meeting of the Brazilian Society for Dermatologic Surgery 2015. "Session: Face to Face with the Masters." Porto Alegre, Brazil, 2015.
4. Annual Meeting of the Brazilian Society for Dermatologic Surgery 2015. "Preoperative Evaluation." Porto Alegre, Brazil, 2015.
5. 71<sup>st</sup> Annual Meeting of the Brazilian Society of Dermatology (SBD). "Treatment of the periorbital region: Phenol and TCA peels", Porto Alegre, Brazil, 2016.
6. 71<sup>st</sup> Annual Meeting of the Brazilian Society of Dermatology (SBD). "Chemical Peels: Modified Deep Peels", Porto Alegre, Brazil, 2016.
7. 71<sup>st</sup> Annual Meeting of the Brazilian Society of Dermatology (SBD). "Global Facial Treatment: Chemical Peels", Porto Alegre, Brazil, 2016.
8. 71<sup>st</sup> Annual Meeting of the Brazilian Society of Dermatology (SBD). "Practical Procedures Video Course: Facial and Body Chemical Peels", Porto Alegre, Brazil, 2016.
9. Annual Meeting of the Brazilian Society for Dermatologic Surgery 2017. "Revlite: versatility of the gold-standard of Q-Switched Lasers." Sao Paulo, Brazil, 2017.
10. 72<sup>nd</sup> Annual Meeting of the Brazilian Society of Dermatology (SBD). "Q-switched lasers for melasma, melanosis and post-inflammatory hyperpigmentation" Costa do Sauipe, BA, Brazil, 2017.
11. 72<sup>nd</sup> Annual Meeting of the Brazilian Society of Dermatology (SBD). "Treatment of Melasma with Q-Switched Nd-YAG and superficial peels" Costa do Sauipe, BA, Brazil, 2017.
12. American Academy of Dermatology (AAD) Annual Meeting 2018. "Melasma: Where do we stand? Chemical Peels." San Diego, CA, USA, 2018.
13. American Academy of Dermatology (AAD) Annual Meeting 2018. "Q-Switched Nd:YAG and Modified Jessner's Solution for Melasma." San Diego, CA, USA, 2018.
14. American Academy of Dermatology (AAD) Annual Meeting 2018. "QT Prolongation as a Safety Signal for Deep Peels" San Diego, CA, USA, 2018.
15. American Academy of Dermatology (AAD) Annual Meeting 2018. "QTc Prolongation and Air Safety during Phenol-croton oil peels" San Diego, CA, USA, 2018.
16. American Society for Dermatologic Surgery Meeting (ASDS 2018) "Phenol vs Croton oil Peels" Core curriculum in chemical peels course. Phoenix, AZ, USA, 2018.
17. 1<sup>st</sup> Lipolysis and Lipoatrophy Meeting – Brazilian Dermatology Society (SBD). "Deoxycholic Acid: history and applications". Fortaleza, CE, Brazil, 2019.
18. 1<sup>st</sup> Lipolysis and Lipoatrophy Meeting – Brazilian Dermatology Society (SBD). "Injectable Cosmetic Lipoatrophy". Fortaleza, CE, Brazil, 2019.
19. 1<sup>st</sup> Lipolysis and Lipoatrophy Meeting – Brazilian Dermatology Society (SBD). Live demonstration: "Combining Emptiers with Skinboosters". Fortaleza, CE, Brazil, 2019.

20. American Academy of Dermatology (AAD) Annual Meeting 2019. International Peeling Society – Pre-AAD Session “Lip Augmentation” Washington DC, USA, 2019.
21. American Academy of Dermatology (AAD) Annual Meeting 2019. International Peeling Society – Pre-AAD Session “Safety considerations in phenol-croton oil chemical peels” Washington DC, USA, 2019.
22. American Academy of Dermatology (AAD) Annual Meeting 2019. F067 - Where do We Stand? The Pathogenesis and Treatment of Melasma “Medium-depth peels, light and LASERs for Melasma” Washington DC, USA, 2019.
23. American Academy of Dermatology (AAD) Annual Meeting 2019. F116 - Superficial, Medium, and Deep Chemical Peeling and Relevance in 2019 “The Lip Peel” Washington DC, USA, 2019.
24. American Academy of Dermatology (AAD) Annual Meeting 2019. F116 - Superficial, Medium, and Deep Chemical Peeling and Relevance in 2019 “Safety considerations in phenol-croton oil chemical peels” Washington DC, USA, 2019.
25. American Society for Dermatologic Surgery Meeting (ASDS 2019) “Deep peels update”, Chicago, IL, USA, 2019.
26. The Skin of Color Community Event Series (SOC Event Series, Brown University), Panelist: “Chemical Peels and Lasers in Skin of Color”, Virtual Event, Providence-RI, Oct 2020.
27. American Society for Dermatologic Surgery Meeting (ASDS 2021) “Incorporating Deep Peels in your practice”, Chicago, IL, USA, 2021.
28. American Academy of Dermatology (AAD) Annual Meeting 2022. International Peeling Society – Pre-AAD Session. “Phenol-croton oil peels Histology and History”, Boston, MA, USA, 2022.
29. American Academy of Dermatology (AAD) Annual Meeting 2022. International Peeling Society – Pre-AAD Session. “Safety and Complications of Phenol-croton oil Peels”, Boston, MA, USA, 2022.
30. American Academy of Dermatology (AAD) Annual Meeting 2022. S058 – Alopecia Workup “What’s up with ALOPECIA and COVID-19?” Boston, MA, USA, 2022.
31. American Academy of Dermatology (AAD) Annual Meeting 2022. F040 – Chemical Peeling in 2022: Morning at the Movies. “Actinic Keratoses and Cheilitis” Boston, MA, USA, 2022.
32. American Academy of Dermatology (AAD) Annual Meeting 2022. F040 – Chemical Peeling in 2022: Morning at the Movies. “Body Peels” Boston, MA, USA, 2022.
33. American Academy of Dermatology (AAD) Annual Meeting 2022. F075: Botulinum Toxin latest updates. “Full face rejuvenation with botulinum toxins” Boston, MA, USA, 2022.
34. American Burn Association (ABA) Annual Meeting 2022. “Skin issues: conditions & interventions”, Las Vegas, NV, USA, 2022.
35. American Society for Dermatologic Surgery Meeting (ASDS 2022) “Chemical Peels Workshop”, Denver, CO, USA, 2022.
36. American Academy of Dermatology (AAD) Annual Meeting 2023. F053: Botulinum Toxin latest updates. “Botulinum toxin resistance and neutralizing antibodies” New Orleans, LA, USA, 2023.

37. American Academy of Dermatology (AAD) Annual Meeting 2023. F085: Chemical Peeling in 2023: An International Perspective. "Supporting healing after a deep chemical peel" New Orleans, LA, USA, 2023.
38. American Academy of Dermatology (AAD) Annual Meeting 2023. S024: Alopecia: Work-up and Treatment. "Thinking outside the box: injectable treatments for Hair Loss and current FDA regulatory oversight" New Orleans, LA, USA, 2023.
39. American Academy of Dermatology (AAD) Annual Meeting 2023. Pre-AAD (Global Day, International Peeling Society Session): Peeling Around the World 2023. "Current Evidence of Phenol-croton oil peels for facial photoaging" New Orleans, LA, USA, 2023.
40. American Academy of Dermatology (AAD) Annual Meeting 2024. Pre-AAD (Global Day, International Peeling Society Session): Peeling Around the World 2024. "Current Evidence of Phenol-croton oil peels for facial photoaging" San Diego, USA, March 7, 2024.
41. American Academy of Dermatology (AAD) Annual Meeting 2024. S028 – Complications of Cosmetic Procedures. "Complications of deep peelings" San Diego, USA, March 9, 2024.
42. American Academy of Dermatology (AAD) Annual Meeting 2024. S032 – Pearls from the Masters of Dermatological Surgery. "Dr Wambier's Pearls" San Diego, USA, March 9, 2024.
43. American Academy of Dermatology (AAD) Annual Meeting 2024. F104 – Chemical Peeling in 2024: An International Perspective. "Applicators and special moves". San Diego, USA, March 11, 2024.
44. American Academy of Dermatology (AAD) Annual Meeting 2024. F117 – Where do We Stand? The Pathogenesis and Treatment of Melasma. "Chemical Peeling – What's old and new? San Diego, USA, March 11, 2024.
45. American Society for Dermatologic Surgery Meeting (ASDS 2024) "Chemical Peels Workshop", Orlando, FL, USA, 2024.
46. American Society for Dermatologic Surgery Meeting (ASDS 2024) - Chemical Peels for Medical Indications. "Melasma", Orlando, FL, USA, 2024.
47. 27<sup>th</sup> Mount Sinai Winter Symposium, Dec 12-15, 2024. "Chemical Peels – From Potions to Science", New York, NY, USA, 2024.
48. American Academy of Dermatology (AAD) Annual Meeting 2025. Pre-AAD (Global Day, International Peeling Society Session): Peeling Around the World 2025. "Indications and Getting Prepared for Superficial, Medium and Deep Peels" Orlando, USA, March 6, 2025.
49. American Academy of Dermatology (AAD) Annual Meeting 2025. S046 – Complications of Cosmetic Procedures. "Uncomplicating Chemical Peels: Risks and Solutions". Orlando, USA, March 9, 2025.

## REGIONAL

1. Chemical Peels: when I still indicate. Oral Presentation presented at: Cosmiatry Symposium; Ribeirão Preto, Brazil, 2014.
2. Choosing Phenol-Croton Formulas. Oral Presentation presented at: Cosmiatry Symposium; Ribeirão Preto, Brazil, 2014.
3. LASER Treatment of vascular and pigmented lesions. Oral Presentation presented at: IV Ribeirão Preto Dermatology Meeting.; Ribeirão Preto, Brazil, 2015.

4. Hands-on Course on Modified Phenol peels and Blepharopeeling. IV Ribeirão Preto Dermatology Meeting.; Ribeirão Preto, Brazil, 2015.
5. Q-Switched LASER for the treatment of melasma and other hyperchromic lesions. Oral Presentation presented at: 8th DermaRio - Rio de Janeiro State Dermatology Meeting; Rio de Janeiro, Brazil, 2016.
6. Intralesional Injections with Minoxidil. Oral Presentation presented at: 8th DermaRio - Rio de Janeiro State Dermatology Meeting; Rio de Janeiro, Brazil, 2016.
7. Chemical Peels Innovations. Oral Presentation presented at: XXIX Capixaba Dermatology Meeting; Vitória, Brazil, 2016.
8. Keloids: Therapeutical Proposal. Oral Presentation presented at: XXIX Capixaba Dermatology Meeting; Vitória, Brazil, 2016.
9. Practical Course of Chemical Peels. Oral Presentation presented at: XXIX Capixaba Dermatology Meeting; Vitória, Brazil, 2016.
10. Salicylic Acid in PEG and Pyruvic Acid Peels Oral Presentation presented at: V Jornada de Dermatologia de Ribeirão Preto (Ribeirao Preto Dermatology Meeting); Ribeirão Preto, Brazil, 2016.
11. Emptiers for improving the facial contour: Deoxicholic acid vs Triamcinolone. Oral Presentation presented at: V Jornada de Dermatologia de Ribeirão Preto (Ribeirão Preto Dermatology Meeting); Ribeirão Preto, Brazil, 2016.
12. Cosmiatry. Oral Presentation presented at: IV Jornada Acadêmica de Cosmetologia e I Jornada de Farmácia Estética UEPG; Ponta Grossa, Brazil, 2016.
13. Pre-Meeting Morning Course: Medium and Deep Chemical Peels Oral Presentation presented at: 25th South-Brazilian Meeting of Dermatology; Gramado, RS, Brazil, 2017.
14. Emptiers for facial contour (jowl and submental fat) Oral Presentation presented at: 25th South-Brazilian Meeting of Dermatology; Gramado, RS, Brazil, 2017.
15. Treatment of alopecia with injectables and microinfusion drug-delivery Oral Presentation presented at: 25th South-Brazilian Meeting of Dermatology; Gramado, RS, Brazil, 2017.
16. Galderma expert practical workshop. "Metvix Daylight Photodynamic Therapy.", Cascavel, Brazil, 2017.
17. JADERP 2017 (Annual Meeting of Dermatology of Ribeirao Preto); "You only have one chance: Extreme rejuvenation", Ribeirao Preto, Brazil, 2017.
18. Metvix Daylight Course and Workshop - Galderma "Metvix Daylight Photodynamic Therapy", Ribeirao Preto, Brazil, 2017.
19. Music City Scale Symposium for Cosmetic Advances & Laser Education – Virtual Congress. "Minoxidil and Dutasteride Drug Delivery", July 2020.
20. JADERP 2020 – What's new in chemical peels? Brazil, Aug 2020.
21. "Protetores da Pele" (Webmeeting) – Rio de Janeiro Dermatology Society 2020 "The Gabrin Sign" Brazil, Aug 2020.
22. New England Dermatological Society. Virtual Clinical Meeting Hosted by Warren Alpert Medical School (NEDS) 2020 – Phenol Croton oil peels – from potions to science, Providence, RI, Oct 2020.
23. DermaNatal, Dermatology meeting. "Day-to-day Peelings". Brazilian Society of Dermatology, Rio Grande do Norte. Natal, RN, Brazil.

24. Warren Alpert Medical School, Brown University Continued Medical Education: "Janus Kinase inhibitors as the new standard of care for severe Alopecia Areata". Dermatology Ground-rounds lecture, Providence, RI, Jun 2022.
25. Florida Academy of Dermatology (FAD 2023), 2023 Annual Meeting May 19-21, Orlando, FL, USA, 2023. "Drug Tattooing: A new delivery method?"
26. Florida Academy of Dermatology (FAD 2023), 2023 Annual Meeting May 19-21, Orlando, FL, USA, 2023. "Peels: From Potions to Science".
27. 14<sup>th</sup> Rhode Island Burn Center Burn Symposium, Rhode Island Hospital, George Auditorium, March 16, 2023. "New Horizons in Scar Management".

#### INVITED GRAND ROUNDS CME EVENTS

1. University of Miami, Department of Dermatology "Phenol-croton oil peels, from potions to science", Grand-rounds lecture, Miami, FL, USA, Jul 2019.
2. Yale University School of Medicine, Department of Dermatology "Phenol-croton oil peels, from potions to science", Grand-rounds lecture, New Haven, CT, USA, Aug 2019.
3. Alpert Medical School, Brown University. Rhode Island Hospital Continuing Medical Education – Department of Dermatology, Dermatology Grand Rounds Clinical Conference "Lucio's Phenomenon in Leprosy", and Lecture. "COVID-19 Testing and Prophylaxis", Providence, RI, USA, Jun 2020.
4. Mount Sinai Medical School CME, Department of Dermatology "Phenol-croton oil peels, from potions to science", Grand-rounds lecture, New York City, NY, USA, May 2022.
5. Mount Sinai Medical School, Department of Dermatology, Grand Rounds Resident Didactic Session, "Basic Chemical Peels: Superficial and Medium Depth Chemical Peels", New York City, NY, USA, May 2022.
6. University of Tennessee Health Science center – Graduate Medical Education: "Going Deep on Chemical Peels and special indications and precautions in Skin of Color". Dermatology Ground-rounds lecture, Memphis, TN, Sep 23 2022.
7. Honor Health – Continued Medical Education: "Chemical Peels: from potions to science". Department of Dermatology Ground-rounds lecture, Scottsdale, AZ, May 28 2025.

## COORDINATION OF CONTINUED MEDICAL EDUCATION SESSIONS:

### INTERNATIONAL

1. Faculty/instructor. 2018 International Peeling Society (IPS) Hands-On Workshop series. "Advanced chemical peels Hands-on workshop," San Diego, CA, USA, 2018.
2. Chair, 14<sup>th</sup> World Congress of Cosmetic Dermatology. "Pigmentary Disorders," Lima, Peru, 2019.
3. Co-Chair, 24<sup>th</sup> World Congress of Dermatology (WCD). "Basic cosmetic dermatology," Milan, Italy, 2019.
4. Faculty/instructor. 2019 International Peeling Society (IPS) Hands-on Workshop series "Advanced chemical peels Hands-on workshop". February 27 and 28, at the Dermatologic Surgery Center of Washington LLC, Maral Skelsey, MD, Washington, DC, USA, 2019.
5. Faculty/instructor. "Hands-on Workshop of Chemical Peels". Aesthetics 2019, Delhi, India, 2019.
6. Faculty. "International Peeling Society (IPS) Online-Academy – Webinar Series. IPS, Muttentz, Switzerland, March-October 2021.
7. Chair. "Chemical Peels"- – International Peeling Society Session at the 23<sup>rd</sup> CILAD – Madrid, Spain July, 2022.
8. Chair. "COVID-19 Discussion" – World Congress of Hair Research 2022. Melbourne VIC, Australia, November 2022.
9. Chair. "Peeling Around the World 2023" – International Peeling Society. Global day AAD March 2023, New Orleans, LA, USA.
10. Chair: "New research and development in Androgenetic Alopecia" – 5<sup>th</sup> Conference Trichology Update, Mumbai, India, June 2023,
11. Chair: 42<sup>nd</sup> Annual Meeting of the International Society for Dermatologic & Aesthetic Surgery. Session 16 – HAIR RESTORATION Medical-Minimally-Invasive-Surgical. Rio de Janeiro, Brazil. September 28-30, 2023.
12. Chair: 32<sup>nd</sup> European Academy of Dermatology and Venerology meeting (EADV). Session: Peeling. Berlin, Germany, October 11-14, 2023.
13. Co-Chair: 32<sup>nd</sup> European Academy of Dermatology and Venerology meeting (EADV). Session: IPS – International Peeling Society "Chemical Peelings – past, present and future". Berlin, Germany, October 14, 2023.
14. Chair: Chemical Peeling Conference. Advanced Session. Praxisklinik Kreyden, Basel, Switzerland, November 17, 2023.
15. Faculty/instructor. X Congreso Peruderm. Chemical Peel and Mesotherapy Live Workshop. Lima, Peru, November 22, 2023.
16. Chair: "Chemical Peels in 2023" – X Congreso Peruderm, Lima, Peru, November 23, 2023.
17. Faculty/instructor. X Congreso Peruderm. Upper Third Live Workshop. "Botulinum toxin A dilutions and injection technique: Microtox and Hypertox dilutions". Lima, Peru, November 25, 2023.

18. Co-Chair: "What do experts think about hot topics?" 22nd Aesthetic & Anti-aging World Congress (AMWC 2024), Monaco, March 30 - April 01 2023. Session: Chemical Peeling Experts on Hot Peeling Topics. Lecture: "What's the role of Deep Peeling in the treatment of Melasma".
19. Co-Chair: "Chemical Peeling Experts on Hot Peeling Topics" – In Collaboration with the International Peeling Society. 22nd Aesthetic & Anti-aging World Congress (AMWC 2024), Monaco, March 27, 2024.
20. Faculty: "Chemical Peeling Live Demonstration of Deep Peeling" – In Collaboration with the International Peeling Society. 22nd Aesthetic & Anti-aging World Congress (AMWC 2024), Monaco, March 28, 2024.
21. Chair: 1<sup>st</sup> International Master Course on Aging Science (IMCAS) Americas 2024, Sao Paulo, April 27, 2024. "Chemical Peels & Mesotherapy (in collaboration with IPS)".
22. Chair: 1<sup>st</sup> International Master Course on Aging Science (IMCAS) Americas 2024, Sao Paulo, April 27, 2024. "Regenerative medicine in hair loss: the battle".
23. 1st Sinmelasma June 7-9, 2024 Bogotá, Colombia - International Society of Melasma and other pigmentary disorders. Faculty - "Peeling, live demo".
24. Chair: Innovations on chemical peeling (in collaboration with IPS), January 31, 2025. IMCAS 2025, Paris, France.
25. Chair: Biohacking, January 31, 2025. IMCAS 2025, Paris, France.
26. Chair: FOCUS SESSION: lectures covering a major topic of the congress. Comprehensive hair and scalp care, February 1, 2025. IMCAS 2025, Paris, France.

#### NATIONAL

27. Chair, 69<sup>th</sup> Annual Meeting of the Brazilian Society of Dermatology (SBD). Session: "Chemical Peels". Recife, Brazil, 2014.
28. Faculty/instructor. "PC02 Hands-on Workshop: Superficial to Deep Chemical Peels" 2019 American Society for Dermatologic Surgery Meeting, Chicago, IL, October 23, 2019.
29. Faculty/instructor. "Chemical Peels Workshop" 2021 American Society for Dermatologic Surgery Meeting, Chicago, IL, October 14, 2021.
30. Main instructor, Advanced Chemical Peels Workshop - University Extension Course 2015 - State University of Ponta Grossa - UEPG. 1<sup>st</sup> and 2<sup>nd</sup> Hands-on Comprehensive course of chemical peels; Belo Horizonte, MG, Brazil, 2015.
31. Main instructor, Advanced Chemical Peels Workshop - University Extension Course 2015 - State University of Ponta Grossa - UEPG. 3<sup>rd</sup> and 4<sup>th</sup> Hands-on Comprehensive course of chemical peels; Balneário do Camboriú, SC, Brazil, 2015.
32. Main instructor, Advanced Chemical Peels Workshop - University Extension Course 2015 - State University of Ponta Grossa - UEPG. 5<sup>th</sup> and 6<sup>th</sup> Hands-on Comprehensive course of chemical peels; Ponta Grossa, PR, Brazil, 2015.



33. Main instructor, Advanced Chemical Peels Workshop - University Extension Course 2015 - State University of Ponta Grossa - UEPG. 7<sup>th</sup> and 8<sup>th</sup> Hands-on Comprehensive course of chemical peels; Porto Alegre, RS, Brazil, 2015.
34. Main instructor, Advanced Chemical Peels Workshop - University Extension Course 2015 - State University of Ponta Grossa - UEPG. 9<sup>th</sup> and 10<sup>th</sup> Hands-on Comprehensive course of chemical peels; Bauru, SP; Brazil, 2015.
35. Main instructor, Advanced Chemical Peels Workshop - University Extension Course 2016 - State University of Ponta Grossa - UEPG. 11<sup>th</sup> and 12<sup>th</sup> Hands-on Comprehensive course of chemical peels; Ribeirão Preto, SP, Brazil, 2016.
36. Main instructor, Advanced Chemical Peels Workshop - University Extension Course 2016 - State University of Ponta Grossa - UEPG. 13<sup>th</sup> and 14<sup>th</sup> Hands-on Comprehensive course of chemical peels; São Paulo, SP, Brazil, 2016.
37. Main instructor, Advanced Chemical Peels Workshop - University Extension Course 2016 - State University of Ponta Grossa - UEPG. 15<sup>th</sup> and 16<sup>th</sup> Hands-on Comprehensive course of chemical peels; São José dos Campos, SP, Brazil, 2016.
38. Main instructor, Advanced Chemical Peels Workshop - University Extension Course 2016 - State University of Ponta Grossa - UEPG. 17<sup>th</sup> and 18<sup>th</sup> Hands-on Comprehensive course of chemical peels; São Luis, MA, Brazil, 2016.
39. Main instructor, Advanced Chemical Peels Workshop - University Extension Course 2016 - State University of Ponta Grossa - UEPG. 19<sup>th</sup> and 20<sup>th</sup> Hands-on Comprehensive course of chemical peels; Natal, RN; Brazil, 2016.
40. Main instructor, Advanced Chemical Peels Workshop Oral Presentation presented at: 21st Hands-on Comprehensive course of chemical peels; Ponta Grossa, Brazil, 2016.
41. Main instructor, Advanced Chemical Peels Workshop Oral Presentation presented at: 22nd Hands-on Comprehensive course of chemical peels; Porto Alegre, Brazil, 2017.
42. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 1st Hands-on course on Emptiers; Porto Alegre, Brazil, 2017.
43. Main instructor, Advanced Chemical Peels Workshop Oral Presentation presented at: 23rd Hands-on Comprehensive course of chemical peels; Ponta Grossa, Brazil, 2017.
44. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 2nd Hands-on course on Emptiers; Ponta Grossa, Brazil, 2017.
45. Main instructor, Advanced Chemical Peels Workshop Oral Presentation presented at: 24th Hands-on Comprehensive course of chemical peels; Ribeirao Preto, Brazil, 2017
46. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 3rd Hands-on course on Emptiers; Ribeirão Preto, Brazil, 2017
47. Main instructor, 5-hours Practical Workshop on Chemical Peels - From Superficial to Deep. JADERP (Annual Meeting of Dermatology of Ribeirao Preto); Ribeirao Preto, Brazil, 2017.
48. Main instructor, Advanced Chemical Peels Workshop Oral Presentation presented at: 25th Hands-on Comprehensive course of chemical peels; São Paulo, Brazil, 2017.
49. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 4th Hands-on course on Emptiers; São Paulo, Brazil, 2017.
50. Main instructor, Advanced Chemical Peels Workshop Oral Presentation presented at: 26th Hands-on Comprehensive course of chemical peels; Ponta Grossa, Brazil, 2017.

51. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 5th Hands-on course on Emptiers; Ponta Grossa, Brazil, 2017.
52. Main instructor, Drug tattooing. Oral Presentation and hands-on trainer at: 1st Hands-on course on Drug Delivery; Ponta Grossa, Brazil, 2017.
53. Chair, 72<sup>nd</sup> Annual Meeting of the Brazilian Society of Dermatology (SBD). Session "Chemical Peels". Costa do Sauipe, BA, Brazil, 2017.
54. Main instructor, Advanced Chemical Peels Workshop Oral Presentation presented at: 27th Hands-on Comprehensive course of chemical peels; Ponta Grossa, Brazil, 2017.
55. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 6th Hands-on course on Emptiers; Ponta Grossa, Brazil, 2017.
56. Main instructor, Advanced Chemical Peels Workshop. Oral Presentation presented at: 28th Hands-on comprehensive course of chemical peels; Ponta Grossa, Brazil, 2018.
57. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 7th Hands-on course on Emptiers; Ponta Grossa, Brazil, 2018.
58. Main instructor, Drug tattooing. Oral Presentation and hands-on trainer at: 2nd Hands-on course on Drug Delivery; Ponta Grossa, Brazil, 2017.
59. Main instructor, Advanced Chemical Peels Workshop. Oral Presentation and hands-on trainer at: 29th Hands-on comprehensive course of chemical peels; Ribeirao Preto, Brazil, 2018.
60. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 8th Hands-on course on Emptiers; Ribeirao Preto, Brazil, 2018.
61. Main instructor, Advanced Chemical Peels Workshop. Oral Presentation and hands-on trainer at: 30th Hands-on comprehensive course of chemical peels; Vitoria, Brazil, 2018.
62. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 9th Hands-on course on Emptiers; Vitoria, Brazil, 2018.
63. Main instructor, Advanced Chemical Peels Workshop. Oral Presentation and hands-on trainer at: 31st Hands-on comprehensive course of chemical peels; Rio de Janeiro, Brazil, 2018.
64. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 10th Hands-on course on Emptiers; Rio de Janeiro, Brazil, 2018.
65. Main instructor, Advanced Chemical Peels Workshop. Oral Presentation and hands-on trainer at: 32nd Hands-on comprehensive course of chemical peels; São Paulo, Brazil, 2018.
66. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 11th Hands-on course on Emptiers; São Paulo, Brazil, 2018.
67. Main instructor, Advanced Chemical Peels Workshop. Oral Presentation and hands-on trainer at: 33rd Hands-on comprehensive course of chemical peels; Fortaleza, Brazil.
68. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 12th Hands-on course on Emptiers; Fortaleza, Brazil, 2019.
69. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 13th Hands-on course on Emptiers; Fortaleza, Brazil, 2019.
70. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-on trainer at: 14th Hands-on course on Emptiers; Fortaleza, Brazil, 2019.
71. Main instructor, Drug tattooing. Oral Presentation and hands-on trainer at: 3rd Hands-on course on Drug Delivery; Fortaleza, Brazil.

72. Main instructor, Advanced Chemical Peels Workshop. Oral Presentation and hands-on trainer at: 34th Hands-on comprehensive course of chemical peels; São Paulo, Brazil, 2019.
73. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-RA trainer at: 15th Hands-on course on Emptiers; São Paulo, Brazil, 2019.
74. Faculty/instructor. Live Patient Demonstrations and Hands-on Workshop: Chemical Peels. October 23, 9:00 am – 4:00 pm. American Society for Dermatologic Surgery Meeting. Hyatt Regency, Chicago, 2019.
75. Main instructor, Advanced Chemical Peels Workshop. Oral Presentation and hands-on trainer at: 35th Hands-on comprehensive course of chemical peels; Ponta Grossa, Brazil, 2019.
76. Main instructor, Advanced Chemical Peels Workshop. Oral Presentation and hands-on trainer at: 36th Hands-on comprehensive course of chemical peels; São Paulo, Brazil, 2019.
77. Main instructor, Deoxycholic acid vs Triamcinolone. Oral Presentation and hands-RA trainer at: 16th Hands-on course on Emptiers; São Paulo, Brazil, 2019.
78. Faculty/instructor. Live Patient Demonstrations and Hands-on Workshop: Chemical Peels. American Society for Dermatologic Surgery Meeting (ASDS 2022), Denver, CO, USA, 2022.
79. Main instructor, Advanced Chemical Peels Workshop. Oral Presentation and hands-on trainer at: 37th Hands-on comprehensive course of chemical peels; June 3 2023, Milwaukee, WI, USA.
80. Main instructor, Drug tattooing. Oral Presentation and hands-on trainer at: 4th Hands-on course on Drug Delivery; June 3 2023, Milwaukee, WI, USA.
81. Main instructor, Advanced Chemical Peels Workshop. Oral Presentations and hands-on trainer at: 38th Hands-on comprehensive course of chemical peels; October 1 2023, Sao Paulo, SP, Brazil.
82. Faculty/instructor. Fall International Peeling Society (IPS-USA) Chemical Peeling Workshop Dermagnify, Ponte Vedra, FL, October 6-7, 2023.
83. Faculty/instructor. Pre-AAD International Peeling Society (IPS-USA) Advanced Chemical Peeling Workshop, Dermatology Institute, Chula Vista, CA, March 6-7, 2024.
84. Main instructor, Drug tattooing. Oral Presentation and hands-on trainer at: 5th Hands-on course on Drug Delivery, "Master Drug Tattooing"; March 10, 2024, San Diego, CA, USA.
85. Main instructor, Advanced Chemical Peels Workshop. Oral Presentations and hands-on trainer at: 39th Hands-on comprehensive course of chemical peels; April 25, 2024, Sao Paulo, SP, Brazil.
86. Main instructor, Drug tattooing. Oral Presentation and hands-on trainer at: 6th Hands-on course on Drug Delivery, "Master Drug Tattooing"; October 19, 2024, Orlando, FL, USA.
87. Faculty/Moderator. Live Patient Demonstrations – Rejuvenation without fillers and botulinum toxin. "Medium depth and Phenol-croton oil peel" with Dr Harold Brody. American Society for Dermatologic Surgery Meeting (ASDS 2024), Orlando FL, USA, 2024.
88. Faculty/Instructor. Live Patient Demonstrations – Rejuvenation without fillers and botulinum toxin. "Scalp Drug Delivery of Minoxidil and Dutasteride" Moderator: Dr Deirdre Hooper. American Society for Dermatologic Surgery Meeting (ASDS 2024), Orlando FL, USA, 2024.

89. Chair. Chemical Peels Workshop – 8-hour course on medium and deep chemical peeling. Co-Chair: Dr Seaver Soon. American Society for Dermatologic Surgery Meeting (ASDS 2024), Orlando FL, USA, 2024.
90. Chair. Chemical Peels for Medical Indications. CME Event. Co-Chair: Dr Seaver Soon. American Society for Dermatologic Surgery Meeting (ASDS 2024), Orlando FL, USA, 2024.
91. Main instructor, Advanced Chemical Peels Workshop. Oral Presentations and hands-on trainer at: 40th Hands-on comprehensive course of chemical peels; December 15, 2024, Sasco Hill Surgery Center, Southport, CT, USA. 2024.
92. Main instructor, Advanced Chemical Peels Workshop. Oral Presentations and hands-on trainer at: 41st Hands-on comprehensive course of chemical peels; March 15, 2025, Oasis Dermatology, Winter Park, FL, USA. 2025.
93. Main instructor, Master Injection and Peels Workshop. Hands-on trainer. April 10, 2025, São Paulo, Brazil. 2025.

## INVENTIONS

1. Kulesza JE, **Wambier CG**. USPTO patent #11,253,465. "Compositions and methods for treating skin conditions." status: granted. Date of Patent: February 22, 2022.
2. **Wambier CG**, Kulesza JE, Hexsel DM. USPTO Patent #11,576,812. "Methods for reducing body fat". Status: granted. Date of Patent: February 14, 2023.

## **CURRENT GRANTS**

- 1. Croton oil and sodium deoxycholic acid incorporated in nanostructured systems, new proposals for formulation for application in the dermatology and aesthetics  
Approved under training grant call CNPq/MCTI/FNDCT N° 18/2021 - Faixa A – Emerging Groups.**

National Council for Scientific and Technological Development (CNPq)

Type: ANIMAL EXPERIMENTAL STUDY

Collaboration: State University of Ponta Grossa and Brown University.

Role: Co-coordinator

Coordinator: Flavio Beltrame PharmD, PhD.

Brief description: Continued studies on formulations of *Croton tiglium* oil.

Grant: \$90,000 BRL (18,000USD)

Current Effort: 1%

Period: 2022 – 2024

## **PAST GRANTS / INVESTIGATOR INITIATED STUDIES**

### **1. Biologic evaluation of vegetable extracts of medicinal and nutraceutical plants**

National Council for Scientific and Technological Development (CNPq)

Type: ANIMAL EXPERIMENTAL STUDY

Collaboration: State University of Ponta Grossa and Brown University.

Role: Co-Investigator

Principal Investigator: Flavio Beltrame PharmD, PhD.

Brief description: Porcine animal model experiment for the evaluation of outcomes of chemical peels and preparations with *Croton tiglium* oil.

Grant: \$30,000 USD

Current Effort: 1%

Project period: 01/2016 – 12/2021

### **2. Research in alopecia areata**

The Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research.

Type: RESEARCH GRANT FUND

Yale Center for Clinical Investigation.

Brief description: Research about scalp surface area and applicability of JAK inhibitors, including combination therapy. Clinical trials and retrospective studies.

Role: Sub-Investigator.

Principal Investigator: Brett King, MD, PhD.

07/2018 – 12/2019

### **3. Chemical Evaluation of vegetable extracts of medicinal and nutraceutical plants**

National Council for Scientific and Technological Development (CNPq)

Type: LABORATORY RESEARCH

Collaboration: State University of Ponta Grossa, University of Mississippi, Oxford, MS and Yale University.

Brief Description: Pharmacognosy of Croton oil: Identification and quantification of Phorbol-esters/diterpenes by high performance chromatography studies in different fractions of croton oil, different batches and suppliers, seasonal variability, stability of Hetter's Stock inside refrigerator and in air temperature, interactions of croton oil complex matrix with septisol, water and phenol in chemical peels solutions.

Role: Co-Investigator

Principal Investigator: Flavio Beltrame PharmD, PhD.

Total costs for project period: \$20,000 USD

Project period: 01/2016 – 12/2019

#### **4. Treatment of sarcoidosis and granuloma annulare with tofacitinib**

Pfizer, Inc.

Type: INVESTIGATOR INITIATED CLINICAL TRIAL GRANT

Yale Center for Clinical Investigation.

Brief description: Evaluation of therapeutic potential of Tofacitinib in patients with systemic sarcoidosis and granuloma annulare.

Role: Sub-Investigator

Principal Investigators: William Damsky, MD, PhD and Brett A. King, MD, PhD

01/2019 – 12/2019

#### **5. Cutaneous adverse reactions to drugs.**

Araucaria Foundation

Type: GRADUATE STUDENT INVESTIGATOR GRANT (PIBIC)

Collaboration State University of Ponta Grossa and University of Sao Paulo

Brief Description: Evaluation of clinical characteristics and validation of the prognostic scale SCORTEN in SJS/TEN in Brazilian patients with and without AIDS (retrospective cohort study) admitted and treated in a single center, University Hospital from 2007 to 2017.

Role: Medical Student Research Advisor

Grant: \$5,000 USD

Project period: 06/2017 – 06/2018

#### **6. Perfecting teaching skills program (PAE/USP).**

University of Sao Paulo

Type: ACADEMIC DEVELOPMENT GRANT

Ribeirao Preto School of Medicine, University of São Paulo.

Brief description: Theoretical and practical activities within the course RCG 0510- Integrated Rotation in Health Centers. This rotation has the goal to develop diagnostic and therapeutic skills in primary care during for 5th year medical school students. Assignment: Management and discussion of dermatologic cases. (work hours: 20h/week);

Grant: \$24,000 USD

Grant period: 02/2009 – 02/2011.



**7. Evaluation of NFkB activation in leprosy**

**National Council for Scientific and Technological Development (CNPq)**

**Type: LABORATORY INVESTIGATION, MD-PhD Student Research Grant.**

University of São Paulo, Brazil. Internal Medicine Clinical Research Postgrad Program.

Brief Description: Leprosy Immunology studies.

Role: Principal Investigator

Grant: \$10,000 USD

Grant period: 02/2009 – 02/2012.

**8. Evaluation of Substitutive MDT in leprosy**

**FAEPA – Foundation for Research and Academics and Paulista Foundation Against Leprosy**

**Type: Clinical Trial**

University of São Paulo, Brazil. Internal Medicine Clinical Research Postgrad Program

Brief Description: Evaluation liver function and hepatotoxicity to antibiotic therapy.

Role: Advisor to a Graduate Medical Student Project

Grant: \$10,000 USD

Grant period: 02/2010 – 02/2011.

**9. Immunomodulator effect of BCG-id in Leprosy**

**National Council for Scientific and Technological Development (CNPq) and Paulista Foundation Against Leprosy**

Type: CLINICAL INVESTIGATION. Research grant.

University of São Paulo, Brazil. Internal Medicine Clinical Research Postgrad Program.

Brief Description: The use of bacillus Calmette-Guérin (BCG) has long been considered a stimulus for immune reactivity in leprosy household contacts. The clinical evaluation suggests that BCG-id is able to induce a more effective therapeutic response with reduction of the number and the intensity of leprosy reactions. These results suggest that BCG-id induces activation of initial phase of immunocellular activity: innate human immunity.

Role: Investigator

Total grant: \$100,000 USD

Grant period: 02/2006 – 02/2011.

## **10. Dermatoses in Diabetes Mellitus**

FAEPA – Foundation for Research and Academics

Type: Clinical Investigation, Resident Research Grant.

University of São Paulo, Brazil. Internal Medicine Clinical Research Postgrad Program.

Brief Description: Skin lesions in DM1 and DM2, in a survey of HbA1c levels.

Role: Principal Investigator

Advisor: Prof. Norma T. Foss, MD, PhD.

Total costs for subproject: \$20,000 USD

Grant period: 02/2005 – 02/2009.

## **11. Porphyrin levels during photodynamic therapy**

National Council for Scientific and Technological Development (CNPq)

Type: Graduate Student Investigator Grant (PIBIC)

Ribeirao Preto School of Medicine, University of Sao Paulo

Brief Description: Evaluation of plasma and urinary porphyrin levels during systemic photodynamic therapy with hematoporphyrin derivative.

Role: Principal Investigator.

Advisor: Prof. Norma T. Foss, MD, PhD.

Total costs for subproject: \$4,000 USD

Grant period: 01/2002 – 01/2003

## **12. Cardiac safety of phenol-croton oil peels**

Type: CLINICAL INVESTIGATION

Brief Description: Past collaborative study of Holter monitoring. Cardiology Division:

Cardiologic studies on Phenol-croton oil compared to medium depth peels: Holter, 12-lead ECG, QTc prolongation, arrhythmic events, RR variability, possible mechanisms of heart toxicity by phenol and croton oil. Collaboration with Andre Schmidt, MD, PhD, Ribeirao Preto School of Medicine, University of Sao Paulo -Role: PI (Sponsor-Investigator).

Total costs for project period: \$10,000 USD

Status: complete. Results published.

Project period: 01/2016 – 06/2018.

### **13. Safety of Phenol-croton oil peels**

Investigator initiated research

Type: LABORATORY RESEARCH

Collaboration: Columbia University

Brief Description: Current collaborative study with the Department of Pharmacology, Columbia University, NY: Ion channel in vitro studies to elucidate mechanisms of QTc prolongation during Phenol-croton oil peels: hERG assay, Phenol, Croton oil, Croton oil fractions. Collaboration with Robert S. Kass, MD, PhD and Kevin Sampson, PhD.

Status: preliminary results complete. Not published. -Role: PI (Sponsor-Investigator)

Project period: 06/2018 – 12/2019.

### **14. In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity (NCT04368897)**

Type: Non-interventional Clinical Investigation.

Brief description: Evaluation of CAG repeats in Androgen Receptor, exon 1.

Status: complete. preliminary results published: 10.1111/jdv.16956.

Sponsor: Applied Biology, Inc. - Role: Study Director and Co-Investigator

Principal Investigator: Sabrina Herrera, MD, PhD.

03/2020 – 08/2020

### **15. ANDROCoV: Anti-Androgen Treatment for COVID-19 (NCT04446429)**

Brief description: Randomized, double-blinded, placebo-controlled clinical trial of anti-androgenic therapy (Proxalutamide) for male COVID-19 outpatients.

Status: complete. Results published. 10.3389/fmed.2021.668698 (Senior author).

Sponsor: Kintor Pharmaceuticals, Applied Biology, Inc. -Role: Co-Investigator

Principal Investigator: Flavio Cadegiani, MD, PhD.

04/2020 – 01/2021

### **16. EAT-DUTA AndroCoV Trial: Early Anti-Androgen Treatment for COVID-19 (NCT04729491)**

Brief description: Randomized, double-blinded, placebo-controlled clinical trial of anti-androgenic therapy (Dutasteride) for male COVID-19 outpatients.

Status: complete. Results published. 10.7759/cureus.13047

Sponsor: Corpometria and Applied Biology, Inc. -Role: Study Safety Director  
Principal Investigator: Flavio Cadegiani, MD, PhD.  
04/2020 – 12/2020

**17. A Study to Investigate Scalp Innervation in Male Androgenetic Alopecia**

Brief description: Testing of scalp sensation on patients with multiple degrees of androgenetic alopecia  
Status: Complete. Results published. - Role: Principal Investigator  
06/2020 – 12/2020.

**18. The Impact of the COVID-19 Pandemic on Dermatologists**

Brief description: Evaluating the impact of the pandemic and diagnosis of COVID-19 in residency, teaching, and care.  
Status: Complete. Results published. - Role: Sub-I.  
Principal Investigator: Tiffany Libby, MD.  
07/2020 – 10/2021.

**19. A randomized, single-blind, parallel-group study to evaluate the efficacy of famciclovir versus isoquercetin in the prevention of Coronavirus Disease 2019 (COVID-19) among healthcare workers.**

Brief description: RCT to evaluate 2 potential drugs for COVID-19  
Status: Withdrawn. Role: Sub-I, Clinical Trial Design.  
Principal Investigator: Gerald J Nau, MD, PhD  
04/2020 – 6/2020.

## **CURRENT INVESTIGATOR-INITIATED STUDIES**

### **20. A Study of the Effects of Tildrakizumab (ILUMYA) use on Epigenetic Aging and Psoriasis (NCT04446429)**

Brief description: Open Label study of anti-IL23 therapy for psoriasis and DNA methylation.

Status: Closed.

Funding: Sun Pharmaceuticals, Inc.

Role: Principal Investigator

06/2020 –

Current Effort: 10%

Grant: 388,985 USD

**CURRENT SPONSORED/FUNDED CLINICAL TRIALS:**

**ALOPECIA AREATA**

**2. A Phase 2 Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata. CP543.5001 (NCT03898479)**

Sponsor: Concert Pharmaceuticals

Role: Principal Investigator

03/2019-

Current Effort: 30%

**PREVIOUS SPONSORED/FUNDED CLINICAL TRIALS:**

**ALOPECIA AREATA:**

**1. A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata CP543.2004 (NCT04784533)**

Sponsor: Concert Pharmaceuticals

Role: Principal Investigator

01/2021-12/2023

**2. 1. A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata CP543.3001 (NCT04518995)**

Sponsor: Concert Pharmaceuticals

Role: Principal Investigator

10/2020-02/2022

**3. A Phase 2a Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata. CP543.2001 (NCT03137381)**

Sponsor: Concert Pharmaceuticals

Role: Sub-Investigator

08/2018-12/2019

**4. A Phase 2a Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata. CP543.2002 (NCT03811912)**

Sponsor: Concert Pharmaceuticals

Role: Sub-Investigator

02/2019-12/2019

**5. A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-Blind Extension Period And A Cross-Over Open Label Extension Period. B7931005 (NCT02974868)**

Sponsor: Pfizer

Role: Sub-Investigator

08/2018-12/2019

**6. Phase 2 study to evaluate the safety and effectiveness of PF-06651600 in adults and adolescents (12 years and older) who have alopecia areata. B7931005 (NCT02974868)**

Sponsor: Pfizer

Role: Sub-Investigator

08/2018-12/2019

**7. Phase 2 study to evaluate the safety and effectiveness of PF-06651600 in adults and adolescents (12 years and older) who have alopecia areata. B7981015 (NCT03732807)**

Sponsor: Pfizer

Role: Sub-Investigator

03/2019-12/2019

**8. A Study of Baricitinib (LY3009104) in Adults with Severe or Very Severe Alopecia Areata. BRAVE-AA1 (NCT03570749)**

Sponsor: Elli-Lilly

Role: Sub-Investigator

08/2018-12/2019

**ATOPIC DERMATITIS**

**9. A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages  $\geq 2$  Years to  $< 12$  Years) With Atopic Dermatitis (TRuE-AD3, INCB18424-305)**

Role: Sub Investigator

Principal Investigator: Muglia, Jennie, MD

Sponsor: Incyte Corporation

12/2021-04/2023

**SARCOIDOSIS AND GRANULOMA ANNULARE:**

**10. Investigator Initiated Clinical Trial of the Efficacy of Tofacitinib for Systemic Sarcoidosis and Granuloma Annulare**

Funding: Pfizer

Role: Sub-Investigator

08/2018-01/2019

**HIDRADENITIS SUPPURATIVA:**

**11. A Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa BE HEARD II (NCT0424298) HS0003**

Sponsor: UCB Biopharma SRL

Role: Principal Investigator

04/2021-04/2022

**12. A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa BE HEARD EXT (NCT04901195) HS0005**

Sponsor: UCB Biopharma SRL

Role: Principal Investigator

04/2022-11/2024



**COVID-19**

**13. A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate The Efficacy And Safety Of Nitazoxanide For Post-Exposure Prophylaxis Of Covid-19 And Other Viral Respiratory Illnesses In Healthcare Workers**

Sponsor: Romark

Status: Withdrawn

Role: Principal Investigator May 2020; Sub-Investigator Aug 2020.  
05/2020-08/2020.

**14. A Randomized, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects**

Sponsor: Suzhou Kintor Pharmaceuticals, Inc.

Role: Sub-investigator

02/2022-11/2022 – Withdrawn by Sponsor.

**PSORIASIS**

**14. PSoSA (PSOoriasis Special Areas) - a US-based, Single- Arm, Prospective, Multicenter, Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated with Ixekizumab**

Sponsor: Eli Lilly and Company

Role: Principal Investigator

10/2022-10/2024

## **UNIVERSITY TEACHING, ADVISING and MENTORING ROLES**

### **1. Division of Dermatology, University of Sao Paulo. (FMRP-USP) 02/2009-02/2012.**

**Course Instructor, RCG 0510:** Integrated Rotation in Health Centers, Ribeirao Preto School of Medicine, University of Sao Paulo, SP, Brazil. 5 rotation classes per year. Average rotation class size: 20 medical students, work hours: 20h/week, 02/2009-02/2011.

-I was assigned to instruct 5<sup>th</sup> year medical students about the diagnosis and therapy of primary care skin diseases, within the core course of Public Health/Social Medicine. In addition, instructors confer supervision of behavior, communication skills, and posture of medical interns in the context of underserved low socio-educational-economic communities. This course runs for approximately 8 weeks and encompasses basic care in internal medicine, pediatrics, family medicine, endocrinology, dermatology, psychiatry, rheumatology, neurology, and public health policies. During two years I was the instructor of practical basic primary care in dermatology, including non-invasive minor surgeries in the primary care setting, and the development of prescription skills in the context of limited medication options.

-Since 2009 I have reinstated case-based learning through "small group" discussions, with dictation of proper description of skin lesions for focused chart documentation. To enhance visual diagnosis skills after patient examination.

-I contributed additionally as a lecturer of "Skin Examination: Elementary skin lesions" in the beginning of each course rotation, to give the proper tools for description of skin changes. I wrote test questions with attention to learning objectives of the rotation.

**Course Lecturer, Integrated Rotation in Health Centers,** "Skin Examination: Elementary skin lesions". Ribeirao Preto School of Medicine, University of Sao Paulo, Bimonthly, 02/2009-02/2011, average class size: 20.

**Faculty Mentor, Student Interest Group.** Tutor of "League to Fight Leprosy and of Dermatology "Luis Marino Bechelli" (LCHD-LMB), student organization with chapter at The Academic Center "Rocha Lima". Ribeirão Preto School of Medicine, University of Sao Paulo. 2009-2011.

Brief Description: Faculty advisor during weekly meetings and student seminars (1h). And practical supervision at weekly activities with leprosy patients and families at the School Center of Health – CSE-FMRP-USP. Also, in monthly homecare visits. Volunteer, in students' extracurricular activities. Volunteer work hours: 3 hours per week. 02/2009-09/2011.

Ribeirao Preto School of Medicine Mentoring Program, 2009. Mentee: Karen Yamashiro, MD '12. Graduate Research.

Yamashiro K, Correa NC, et al. Retrospective study of cases of leprosy examined by the student League of Leprosy "Luiz Marino Bechelli" from 1998 to 2007. Revista Medicina. 2009, Dec; 42(S1): 13-13.

Ribeirao Preto School of Medicine Mentoring Program, 2010. Mentee: Natália Correia, MD '12. Graduate Research.

Correa NC et al. Leprosy treatment: an evaluation of substitutive therapy to standard multi-drug regimen. *Hansenologia Internationalis*. 2010, Jul; 35(1): 67-67.

Correa NC et al. Change in liver function tests associated with leprosy multi-drug therapy. *Hansenologia Internationalis*. 2010, Jul; 35(1): 38.

## 5. University of Ribeirao Preto Medical School. (UNAERP) 08/2010-09/2011

**Course Director, Dermatology:** 5 rotation classes per year. Average rotation class size: 16 (4<sup>th</sup> year medical students), work hours: 5h/week, 08/2010 - 09/2011.

-I designed a comprehensive course for 4<sup>th</sup> year medical students for developing visual diagnosis skills and awareness of basic dermatologic therapeutic resources. The students were assigned seminars about different presentation of skin diseases. The class was divided into small groups of 8 students.

-I contributed additionally as a lecturer of "Skin Examination: Elementary skin lesions" and "Leprosy Update" in the beginning and the end of each course rotation. I wrote test questions with attention to learning objectives and the presented seminars.

**Course Lecturer, Dermatology,** "Skin Examination: Elementary skin lesions". University of Ribeirao Preto Medical School. 08/2010-09/2011, average class size: 16. Two classes per year.

**Course Lecturer, Dermatology,** "Leprosy Update". University of Ribeirao Preto Medical School. 08/2010-09/2011, average class size: 16. Two classes per year.

**Course Director, Dermatology Elective:** Average rotation class size: 2 (5<sup>th</sup> year medical students). Shadowing in private practice. Work hours: 5h/week, 08/2010 - 09/2011.

**Course Instructor, Clinical Skills:** 5 rotation classes per year. Average rotation class size: 16 (5<sup>th</sup> year medical students), work hours: 5h/week, 08/2010-09/2011. Basic dermatology outpatient clinic.

-I designed OSCE questions about dermatology and basic skin surgery. I participated in OSCE examinations stations of clinical skills would take place every 6 months and were intended to give medical students enough preparation for Residency Practical Examination (part of the Medical Residency Entrance Exams, in Brazil).

University of Ribeirao Preto Medical School Mentoring Program, 2010. Mentee: Carolina Pereira, MD '11. Blood Donation in Dermatology. *Graduate Research was awarded during the State of São Paulo Annual Dermatology Meeting (RADESP), #1 Poster Presentation.*

Wambier CG, Pereira CS, Prado BP, Foss NT. Brazilian blood donation eligibility criteria for dermatologic patients. *An Bras Dermatol*. 2012, Jul; 87(4): 590-595. PMID: 22892774.

University of Ribeirao Preto Medical School Mentoring Program, 2011. Mentee: Heloísa Picado, MD'12. Review of imiquimod triggering vitiligo. *Gratuade Research*. Picado HR, et. Al. Vitiligo induced by imiquimod: review and case report. *Revista Medicina*. 2012, Dec; 45(S1): 8-8.

#### 6. **Department of Medicine - State University of Ponta Grossa (UEPG) 06/2013-12/2018.**

**Course Co-director, Dermatology.** Department of Medicine - State University of Ponta Grossa. Academic rotation (4<sup>th</sup> year of medical school), duration: 5 months. Two classes per year. Average rotation class size: 30 medical students, work hours: 5h/week, 06/2013-06/2018.

- I was the course lecturer for 10 classes, including the introductory lecture about dermatologic approach to diagnosis. I wrote test questions with attention to learning objectives of the course. During the course there were two tests.

**Course Lecturer, Dermatology,** "Skin Examination: Elementary skin lesions". University of Ribeirao Preto Medical School. 06/2013-06/2018, average class size: 30. Two classes per year.

**Course Lecturer, Dermatology,** "Tropical Dermatology". Department of Medicine - State University of Ponta Grossa. 06/2013-06/2018, average class size: 30. Two classes per year.

**Course Lecturer, Dermatology,** "Cosmetic Dermatology". Department of Medicine - State University of Ponta Grossa. 06/2013-06/2018, average class size: 30. Two classes per year.

**Course Lecturer, Dermatology,** "Drug Reactions". Department of Medicine - State University of Ponta Grossa. 06/2013-06/2018, average class size: 30. Two classes per year.

**Course Lecturer, Dermatology,** "Psoriasis and Seborrheic Dermatitis". Department of Medicine - State University of Ponta Grossa. 06/2013-06/2018, average class size: 30. Two classes per year.

**Course Lecturer, Dermatology,** "Immunobullous diseases". Department of Medicine - State University of Ponta Grossa. 06/2013-06/2018, average class size: 30. Two classes per year.

**Course Lecturer, Dermatology,** "Acne and Photodamage". Department of Medicine - State University of Ponta Grossa. 06/2013-06/2018, average class size: 30. Two classes per year.

**Course Lecturer, Dermatology,** "Mycosis". Department of Medicine - State University of Ponta Grossa. 06/2013-06/2018, average class size: 30. Two classes per year.

**Course Lecturer, Dermatology,** "Leprosy". Department of Medicine - State University of Ponta Grossa. 06/2013-06/2018, average class size: 30. Two classes per year.

**Course Lecturer, Dermatology**, "Non-melanoma skin cancer". Department of Medicine - State University of Ponta Grossa. 06/2013-06/2018, average class size: 30. Two classes per year.

**Course Instructor, Clerkship in Family Health II**. Clerkship rotation (5<sup>th</sup> year of medical school), duration: 6 months. Two classes per year. Average rotation class size: 30 medical students, work hours: 4h/week, General Dermatology Outpatient Clinic and Regional Psoriasis Clinic. 06/2013-06/2018.

-I designed OSCE questions about dermatology and psoriasis. I participated in OSCE examinations (Every 3 months). Those examinations were intended to give medical students enough preparation for Residency Practical Examination (part of the Medical Residency Entrance Exams, in Brazil). Also, *International Medical Graduates were tested during these OSCE examinations, as part of their medical diploma revalidation in Brazil.*

**Coordinator and Instructor**. Advanced Chemical Peels Workshop - University Extension Course, CME for dermatologists and plastic surgeons, 2015/2016 - State University of Ponta Grossa - UEPG. 02/2015-10/2016.

**Co-Advisor**, Pharmaceutical Sciences Postgraduation Program. Aline da Silva Justo **MSc.'18**. "Chemical Characterization of the Oil of *Croton tiglium* (Euphorbiaceae) and the evaluation of dermatologic profile of phenol-croton oil chemical peel". Dissertation presented for obtaining the title of Master in Sciences in Pharmaceutical Sciences, 04/2016-04/2018.

**Co-Advisor**, Pharmaceutical Sciences Postgraduation Program. Bruna Mikulis Lemes **PhD Student**. Thesis: "Improved emulsion for Phenol-croton oil deep chemical peels". 03/2016-03/2020.

**Co-Advisor**, Pharmaceutical Sciences Postgraduation Program. Aline da Silva Justo **PhD Student**. Thesis: "Evaluation of the effects of Croton Oil as a potential agent in antiaging aesthetic treatments". 04/2018-03/2023.

**Mentor**, Departmental Mentoring Program (DEMED), 2013 and 2014. Mentee: Tayza Katelline Danilau Ostroski, MD'15. Graduate Research Project, Scientific Initiation year in 2014. Clinical and dermoscopic signals of eruptive pseudoangiomatosis:

-Wambier CG, Cappel MA, **Danilau Ostroski TK**, et al. Familial outbreak of eruptive pseudoangiomatosis with dermoscopic and histopathologic correlation. *J Am Acad Dermatol*. 2017, Feb; 76(2S1): S12-S15.

-Wambier CG, **Danilau Ostroski TK** et al. Syringe lubricant and adverse reactions. *Int J Dermatol*. 2018 Jan;57(1):122-123. doi: 10.1111/ijd.13825. Epub 2017 Nov 20.

-**Ostroski TKD** et al. (April, 2016). *Eruptive Pseudoangiomatosis Outbreak in Brazil - Dermoscopy, Histology and Viral Research Findings*. Poster presented at: 24th South Brazilian Dermatology Meeting; Curitiba, Brazil.

**-Ostroski TKD** et al. (September, 2016). *Eruptive Pseudoangiomatosis Outbreak in Brazil - Dermoscopy, Histology and Viral Research Findings* Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.

**Mentor**, Departmental Mentoring Program (DEMED), 2015. Mentee: Leonardo N. Durski, MD'17. Graduate Research Project, Scientific Initiation year in 2015.

-Wambier CG, Struecker TA, **Durski LN** et al. Image Gallery: A case of pemphigus vulgaris following Simulium spp. (Diptera) bites. *Br J Dermatol.* 2017, May; 176(5): e100. PMID: 28504401.

**Mentor**, Departmental Mentoring Program (DEMED), 2015 and 2016. Mentee: Thaís Angelica Hoekstra, MD'18. Graduate Research Project, Scientific Initiation year in 2017, sponsored by Fundação Araucária Grant for Graduate Research (PIBIC).

-Wambier CG, **Hoekstra TA** et al. Epidermal Necrolysis: SCORTEN performance in AIDS and non-AIDS patients. *An Bras Dermatol.* 2019;94(1):17-23 doi: 10.1590/abd1806-4841.20196864:

-Wambier CG, **Hoekstra, TA** et al. (September, 2016). Review of 25 years of cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a University Hospital. Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.

**Mentor**, Departmental Mentoring Program (DEMED), 2016. Karin Barszcz, MD'19. Graduate research project on drug induced hypersensitivity syndrome.

**-Barszcz, K** et al. (April, 2016). A report of 2 cases where drug-induced hypersensitivity syndrome spares leprosy lesions of multibacillary and paucibacillary cases. Poster presented at: 24th South-Brazilian Dermatology Meeting; Curitiba, Brazil.

**-Barszcz K** et al. (June, 2016). *DIHS spares leprosy lesions in multibacillary and paucibacillary cases*. Poster presented at: XXXIV Reunião Anual dos Dermatologistas Latino-Americanos (RADLA) - (Latin-American Meeting); Sao Paulo, Brazil.

**-Barszcz, K** et al. (September, 2016). *Scurvy: The Correlation of Clinic, Dermoscopic and Histopathological findings*. Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.

**-Barszcz, K** et al. (September, 2016). *DIHS spares leprosy lesions in multibacillary and paucibacillary cases*. Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.

**-Barszcz, K** et al. (September, 2016). *Scurvy: The Correlation of Clinic, Dermoscopic and Histopathological findings*. Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.

**-Barszcz, K** et al. (September, 2016). *DIHS spares leprosy lesions in multibacillary and paucibacillary cases*. Poster presented at: 71st Brazilian Society of Dermatology Meeting; Porto Alegre, Brazil.

**Mentor**, Departmental Mentoring Program (DEMED), 2016. Claudia Kuhn, MD'18. Dermatology Couse Volunteer Mentee.

**-Kuhn CA** et al. (June, 2016). *Eruptive Pseudoangiomatosis Outbreak in Brazil - Dermoscopy, Histology and Viral Research Findings*. Poster presented at: XXXIV Reunião Anual dos Dermatologistas Latino-Americanos (RADLA) (Latin-American Meeting); São Paulo, Brazil.

**7. Department of Pharmaceutical Sciences - State University of Ponta Grossa (UEPG) Pharmaceutical Sciences Postgraduation Program, Sector of Biological Sciences and Health, State University of Ponta Grossa.**

**02/2016 – Present**

**1- Doctoral Co-Advisor, 2016-2021**, Bruna Mikulis Lemes “EXPLORING NEW POSSIBILITIES OF FORMULATIONS BASED ON PHENOL-CROTON OIL PEELING with *Croton tiglium* oil”, PhD Thesis in Pharmaceutical Sciences, defended in 2021.

**2- Masters Co-Advisor, 2016-2019**, Aline da Silva Justo “CHEMICAL CHARACTERIZATION OF *Croton tiglium* oil (EUPHORBIACEAE) AND EVALUATION OF THE DERMATOLOGICAL PROFILE OF THE PHENOL-CROTON OIL PEEL”. MSc dissertation in Pharmaceutical Sciences, 2019.

**3- Doctoral co-Advisor, 2019-2023**, Aline da Silva Justo “EVALUATION OF THE EFFECTS OF CROTON OIL AS A POTENTIAL AGENT IN AESTHETIC ANTIAGEING THERAPY.”, PhD Thesis in Pharmaceutical Sciences, defended in 2023.

**4- Collaborator in the project 2021-2022**, Anna Claudia M. O. Capote “Production of liquid crystal as vehicle for dermal absorption of *Croton tiglium* in a chemical peel formulation.



**8. Department of Dermatology – Warren Alpert School of Medicine, Brown University  
01/2020-**

**Research Mentor, Mentee: Soha Ghanian, MD'21**

Departmental Mentoring Program, 2021. Research Project: Drug Delivery through Tattoo Machines

Published peer-reviewed articles:4

**Research and global dermatology mentor, Mentee: Erica Lin, BS, MD'23.**

Departmental Mentoring Program, 2020-2023. Global Health Scholarship, Brown University 2020 -. Research Project: "Lip involvement in pemphigus".

Other research: Environmental factors to COVID-19 vulnerability: altitude and population density, Involvement in a multi-center chemical peels clinical (RCT) and chemistry research (submitted); Daylight Saving Time and COVID-19;

Published peer-reviewed articles:7

**Research Mentor, Mentee: Tatiana Filipa Abrantes, MD'23**

Warren Alpert Medical School of Brown University 2020 -2021. Research Project:

Characteristics of Telogen Effluvium post-COVID-19;

Other research: Environmental factors for COVID-19 in the USA. Tattoo prevalence in beaches during summer by gender and skin type in New England.

Published peer-reviewed articles:1

**Research mentor, Mentee: Ogechi Ezemma, BA, MD'23.**

Warren Alpert Medical School of Brown University 2020-2022. Research Project:

"Characterization of the activity of Croton tiglium oil in Hetter's very heavy phenol-croton oil chemical peels."

Other research: CD3+ cells in Alopecia Areata.

Published peer-reviewed articles:1

**Research Mentor, Mentee: Benjamin Gallo Marin, MD'23**

Warren Alpert Medical School of Brown University 2020 -2021. Research Projects: Seasonality of COVID-19; Education about tattoo removal in YouTube.

Published peer-reviewed articles:1

**Research Mentor, Mentee: Gregory Cavanagh, BS, MD'24.**

Departmental Mentoring Program, 2020. Summer Research Project: "Scalp sensation test in Androgenetic Alopecia" – completed, to be submitted to Nature Reviews Neuroscience.

-Other research: COVID-19 hygiene practices; Seasonality of Skin Diseases. Tattoo prevalence in beaches during summer by gender and skin type in Rhode Island. Training in STATA;

Published peer-reviewed articles:4

**Research Mentor, Mentee: Scott MacDonald, MD'24**

Departmental Mentoring Program, 2021.

Warren Alpert Medical School of Brown University 2020 – Research Project: Antiandrogens in COVID-19; International collaborative research. Principal investigator in the project: Evaluation of lung CT scans in patients with or without the use of Proxalutamide.

Published peer-reviewed articles:3

**Research Mentor, Mentee: Casey Abrahams, BA, MD'24.**

Departmental Mentoring Program, 2020-2022. Research Project: "Silicone oil escape in injectables". -Other research: National survey of dermatologists regarding silicone oil contamination and safety; Tattoo prevalence in beaches during summer by gender and skin type in California. Environmental factors for COVID-19 in New England; Training in RedCap use and STATA;

Published peer-reviewed articles: 2

**Research Mentor, Mentee: Marcelo Paiva, MD'24**

Warren Alpert Medical School of Brown University 2020 -2023. Research Projects: Skin of color burn and repigmentation mechanisms.

Published peer-reviewed articles: 2

**Research Mentor, Mentee: Sara Ragi, MD'24**

Warren Alpert Medical School of Brown University 2022-current -. Research Project: Clinical Efficacy of Minoxidil Sulfate and Dutasteride Administered via Tattoo Equipment in the Treatment of Male Pattern Baldness;

Published peer-reviewed articles: 3

**Research mentor, Mentee: Rachel K. Lim, MD'24**

Brown University 2020 – 2022. Research Project: Hair Biology and therapy.

Published peer-reviewed articles: 5

**Research Mentor, Mentee: Zaim Haq, MD'25**

Warren Alpert Medical School of Brown University 2023-current. Research Project: Control of itch of burn scars with topical JAK inhibitors.

Published peer-reviewed articles: 0

**Research mentor, Mentee: Austin Coopinger, MD'27**

Brown University 2024 –current. Research Project: Injectable Cryolipolysis, Ultrasound measurement with AI, Safety of Chemical Peels, Scalp hair vs Eyebrows preference per sex, safety of 5aRi.

Published peer-reviewed articles: 3

## **9. Brown University 01/2020- Present**

### **Research mentor, Mentee: Rachel K. Lim, AB'21**

Brown University 2020 - Research Project: "Impact of Circadian Rhythm and androgens in COVID-19".

Published peer-reviewed articles: 5

### **Research mentor, Mentee: Angelina Ossimetha, AB'21.**

Brown University 2020 - Research Project: "Androgens and COVID-19".

Published peer-reviewed articles:1

### **Research mentor, Mentee: Nina Mehta, AB'22.**

Research / Review Project: "COVID-19 and Androgens".

Published peer-reviewed articles:1

### **Research mentor, Mentee: Alex Rodriguez, BS'24.**

Research / Review Project: "Beard hair studies".

Published peer-reviewed articles:0

## **10. Bryant University 06/2021- 6/2023.**

**Course Lecturer, Bryant PA Program. Dermatology Classes, "Photodermatology".** Physician Assistant Program – Bryant University, Rhode Island. 06/2021-06/2023, average class size: 30. One class per year.

## **ACADEMIC DEGREE REFEREE BOARDS**

### **Post-Graduation Program: IAMSPE – CEDEP, Sao Paulo, Brazil, 02/2021.**

Role: Title board member of the examining board of qualification for doctoral degree.

PhD Candidate: Fernanda Ayres de Moraes e Silva Cardoso.

Mentor: Prof. Adilson da Costa, MD, PhD

Thesis: "Immune-histochemical evaluation of p53 protein, metalloproteinases, jun-B, anti-collagens and sirtuins, in the neocollagenesis of the aged perioral skin, after treatment with Hetter's phenol-croton oil peel".

### **Post-Graduation Program: IAMSPE – CEDEP, Sao Paulo, Brazil, 04/2021.**

Role: Examining board member for doctoral degree.

PhD candidate: Fernanda Ayres de Moraes e Silva Cardoso.

Mentor: Prof. Adilson da Costa, MD, PhD

Thesis: "Immune-histochemical evaluation of p53 protein, metalloproteinases, jun-B, anti-collagens and sirtuins, in the neocollagenesis of the aged perioral skin, after treatment with Hetter's phenol-croton oil peel".

### **Post-Graduation Program: The National Institute of Laser Enhanced Sciences (NILES) Cairo University, Cairo, Egypt, 01/2021.**

Role: Thesis reviewer, board member of the examining board of qualification for doctoral degree.

PhD Candidate: Heba Effat Mohamed El-Azab

Mentors: Prof. Dr. Mona Mohamed Soliman, MD, PhD, Prof. Dr. Manal Mohamed Salah El-Din, MD, PhD, and Prof. Dr. Maha Fadel Mohamed Ali, PharmD, PhD.

Thesis: "Pulsed dye laser versus photodynamic therapy for the treatment of acne vulgaris".

### **Post-Graduation Program: The National Institute of Laser Enhanced Sciences (NILES) Cairo University, Cairo, Egypt, 09/2021.**

Role: Examining board member for doctoral degree.

PhD Candidate: Heba Effat Mohamed El-Azab

Mentors: Prof. Dr. Mona Mohamed Soliman, MD, PhD, Prof. Dr. Manal Mohamed Salah El-Din, MD, PhD, and Prof. Dr. Maha Fadel Mohamed Ali, PharmD, PhD.

Thesis: "Pulsed dye laser versus photodynamic therapy for the treatment of acne vulgaris".

## **HOSPITAL TEACHING, ADVISING and MENTORING ROLES**

### **Hospital of Clinics of Ribeirao Preto, University of Sao Paulo. (HCFMRP-USP) 02/2009-02/2012.**

**Instructor**, Leprosy Outpatient Clinic, 02/2009-02/2011. The Leprosy Outpatient Clinic of the Hospital of Clinics of Ribeirao Preto is a National Reference Center for the treatment of complex cases of leprosy. The most complex cases were selected and discussed in the end of the morning with senior professors of dermatology and neurology. Patients often required admission for treatment of leprosy reactions or severe drug reactions.

**Instructor**, Primary Dermatology Clinic, 02/2009-02/2011. Low complexity dermatology cases of patients with low resources, and limited prescription options.

**Advisor**, Stevens-Johnson / Toxic Epidermal Necrolysis admissions, 02/2009-02/2012. Due to ongoing prospective clinical study of interventions based on SCORTEN at admission, all cases presented in the Emergency Unit or all suspected cases in the wards of the Hospital of Clinics or AIDS unit (UETDI) were seen before initiation of specific therapy. As part of the protocol, the senior dermatology resident would contact me directly for decision.

**Lecturer**, Resident Core Curriculum, Department of Internal Medicine, Endocrinology Division, Hospital of Clinics, Ribeirao Preto, SP, Brazil. 2009-11. "Skin Manifestations of Diabetes Mellitus."

**Lecturer**, Resident Core Curriculum, Department of Internal Medicine, Dermatology Division, Hospital of Clinics, Ribeirao Preto, SP, Brazil. 2009-11. "Drug Reactions."

**Instructor**, Resident Core Curriculum, Dermatology Division. Primary Dermatologic Surgery Clinic, 06/2009-07/2011. Minor surgeries and the municipal center for the National Program for treatment of HIV-associated facial lipoatrophy with injectable fillers. School of Health Center (CSE-FMRP-USP), 3<sup>rd</sup> year dermatology residents.

**Instructor**, Resident Core Curriculum, Dermatology Division. Phenol-croton oil chemical peels, 2009-12. Cosmetic Dermatology Outpatient Clinic. Senior residents selected cases for hands-on training.

**University Regional Hospital -State University of Ponta Grossa (UEPG) 06/2013-12/2018.**

**Director, Academic Leprosy Clinic**, University Regional Hospital, 08/2013-01/2014. Severe cases of leprosy referred by the city's Leprosy Outpatient Clinic. Direct supervision of 5<sup>th</sup> and 6<sup>th</sup> year medical students.

**Director, the Regional Psoriasis Clinic**, University Regional Hospital, 02/2014-06/2018. Severe psoriasis. Central region of the State of Paraná, direct supervision of residents and 6<sup>th</sup> year medical students.

**Director, Regional Pemphigus Infirmary**, University Regional Hospital 06/2014-06/2018. Severe pemphigus foliaceus or pemphigus vulgaris cases. Admitted for DCP (Dexamethasone-Cyclophosphamide pulse) therapy or Rituximab infusions. Indirect supervision of the Internal Medicine Attending physicians. Once weekly rounds with direct supervision of Residents and Attendings.

**Lecturer**, Resident Core Curriculum, University Regional Hospital, of Ponta Grossa 2014-18. "Drug Reactions", average class size: 50.

**Resident Mentor**, Ponta Grossa Regional Hospital. End of residency monography. Tales Struecker, MD, Internal Medicine Resident. "Endemic Pemphigus Vulgaris, a Review of Literature". Co-author in the article Wambier CG, **Struecker TA**, Durski LN et al. Image Gallery: A case of pemphigus vulgaris following Simulium spp. (Diptera) bites. Br J Dermatol. 2017, May; 176(5): e100. PMID: 28504401.

**Rhode Island Hospital, Brown University Health - 12/2019- present**

**Attending, Dermatologist. Combined Rounds of Burn Surgeon, Dermatologist and Plastic Surgeon. Rhode Island Burn Center**, Rhode Island Hospital 06/2021-current. Post-burn scar cases. Scar management and therapy. Intralesional and drug-delivery therapy. Monthly rounds with direct supervision of rotating Residents, Medical Students, and Fellows.

**Medical Director of Clinical Trials. Dermatology Clinical Trials Center (DCTC)**. Rhode Island Hospital, Jane Brown Building, 01/2021-current. Weekly research administrator and research fellows meeting. Monthly department meetings. Direct supervision of Research Supervisor, Senior Research Assistant, Junior Dermatology Faculty, Clinical Research Fellows, and Clinical Research Interns.

- Direct Supervision of Research Fellows:
  - o Betul Macit, MD: 2023-2025.
  - o Leticia Vidotti, MD: 2025-2026.

## **Brown Dermatology – 01/2020- present**

**Attending, Dermatologist. Advanced Cosmetic Dermatology.** South County Commons 01/2020-current. Neurotoxins, Dermal Fillers, including Hyaluronic Acid, Poly-L-Lactic acid, Calcium Hydroxyapatite, HIV related lipoatrophy, Pulsed Dye Laser (595nm) for vascular lesions, Nd:Yag (1064nm) Long Pulse for vascular and hair, including skin of color, Picosecond 1064nm, 532nm for benign pigmented skin lesions and tattoo removal, fractional picosecond 1064nm and 532nm for acne scars and wrinkles, picosecond 785nm for tattoo removal, CO2 laser, fully ablative and fractional, microneedling chemical peels, advanced chemical peels, electrolysis, body contouring with cosmetic lipoatrophy, deoxycholic acid, injectable cryolipolysis, drug delivery through microneedling, intralesional bleomycin, 5FU, observational sessions for mentoring external dermatologists, Residents, Medical Students, and Fellows.

**Attending, Resident Cosmetic Continuity Clinic:** direct supervision and hands-on training of PGY-4 dermatology Residents. 01/2022- 09/2025.

**Attending, Dermatology Specialty Alopecia Clinic.** South County Commons 01/2022-01/2026. Severe Alopecia cases of androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, lichen planus pilaris, post-covid and post-vaccine hair problems. Direct Supervision of Residents.

## **Brown University. Warren Alpert Medical School, Department of Dermatology Residency Program. 01/2020 -**

**Resident Mentor 2020-2023 program,** Rhode Island Hospital, Eric Yang, MD, Dermatology Resident. Co-author in the article J Am Acad Dermatol . 2021 Jan 28;S0190-9622(21)00222-X. doi: 10.1016/j.jaad.2021.01.065.

**Resident Mentor 2020-2021 program,** Rhode Island Hospital, Hannah Singer, MD, Dermatology Resident.

**Resident Mentor 2021-2023 program,** Rhode Island Hospital, Mayra Maymone, MD, ScD, Dermatology Resident.

**Resident Mentor 2023-2025 program,** Rhode Island Hospital, Andrew Blundell, MD, Dermatology Resident.

**Resident Mentor 2023-2025 program,** Rhode Island Hospital, Esther Henebeng, MD, Dermatology Resident.